










<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd"> 

<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
 
    <title>Updated Treatment for Influenza A and B - American Family Physician</title>
    
    <meta charset="utf-8">



    <meta name="content-type" content="text/html; charset=UTF-8">
    <meta name="viewport" content="width=device-width">



	<script type="text/javascript" src="http://use.typekit.net/anl1nek.js"></script>
    <script type="text/javascript">try{Typekit.load();}catch(e){}</script>
 
   <link rel="stylesheet" href="//css.aafp.net/apps/journals/style.css" type="text/css" media="all" />
    <script type="text/javascript" src="//js.aafp.net/JavaScriptFinal.js"></script> 
    
  
  <script src="http://nf.aafp.org/ScriptManager/Scripts/Aafp.Core.js" type="text/javascript" xmlns:xlink="http://www.w3.org/1999/xlink"></script>
    
    <!-- Replace this if you need application specific JS -->

    <link rel="shortcut icon" type="image/x-icon" href="http://aafp.org/favicon.ico"/>
     
   
	


   	   <link rel="stylesheet" href="/afp/css/journal.css" type="text/css" media="all" />
     <link rel="stylesheet" href="/afp/css/afp.css" type="text/css" media="all" />
     
     
      <script type="text/javascript" src="https://www.aafp.org/jquery.printElement.js"></script>
     

     
       
    <meta name="description" content="Influenza causes significant morbidity and mortality and is responsible for considerable medical expenditures. Vaccination is the most effective public health measure to combat this illness. Amantadine and rimantadine are older antiviral agents that have been important adjuncts in the prevention and treatment of influenza A outbreaks. Zanamivir and oseltamivir are newer agents indicated for the treatment of both influenza A and B. For antiviral agents to be effective, they must be used within 48 hours of the onset of influenza symptoms. Antiviral agents reduce the duration of fever and illness by one to two and one-half days and also reduce the severity of some symptoms. Use of amantadine or rimantadine is appropriate if influenza virus A is known to be the predominant agent in a particular year or location. Data need to be evaluated on the development of resistance and use of the newer antiviral agents in geriatric patients, high-risk patients and children. For optimal use of antiviral agents, patients with influenza symptoms must present early, and family physicians must accurately and rapidly diagnose the illness." />
<meta name="pubdate" content="2000-12-01" />
<meta name="access-restricted" content="false" />
<meta name="content-type-facet" content="Article" />
<meta name="topic" content="Influenza" />
<meta name="discipline" content="Infectious disease" />
<meta name="population" content="" />
<meta name="content-focus" content="Treatment" />

  





<script language="JavaScript" type="text/javascript" src="http://js.aafp.net/omniture/aafp-prod-omniture.js"></script>
<script type="text/javascript"><!--

    
 

    /* Traffic Variables */
	s.pageName="journals:afp:20001201:2467";

	s.referrer=document.referrer  
	 
	
	s.prop1= "updated treatment for influenza a and b";
	s.prop3 = "american family physician";
	
	
    s.prop17= "public";
	    
	s.prop40= "publications"
    s.prop41= "educate"
    s.prop42= "jms"

	/* eVars */
	s.eVar21="";
	s.eVar41= "D=c41"
    s.eVar42="D=c40"
	
	/************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
	var s_code=s.t();if(s_code)document.write(s_code)//-->
	</script>

    <style type="text/css">
.jModal{display:none;}
     #column-wrap { 
  width: 300px; 
  margin: 15px auto; 
  position: relative; 
}


    </style>
    
    
     <!--[if lt IE 9 ]>
     <style type="text/css">
     .gtIE8, .mjToggle, .articleSections{display:none !important;}
     .ltIE8{display:block !important;}   
     </style>
        <![endif]-->
    

    
  </head>

<body class="journal-template">


<script type="text/javascript">


   
    
              $(function () {
        var titleGroup =  $(".titleGroup").clone();         
        var journalCopyright =  $(".journalCopyright").clone(); 
       
        
        var screen_width = $(window).width();
        var screen_height = $(window).height();

        if (screen_width >= 767) { var winW = 650 }

        else if (screen_width < 767 & screen_width > 479) {

            var winW = screen_width - 50;
        }
        else {
            var winW = screen_width - 20;
        };

        if (screen_height > 600) {

            var winH = 500;
        }
        else {
            var winH = screen_height - 50;
        };




        $(".jModal").dialog({
            autoOpen: false,
          
            modal: true,
            resizable: true,
            width: winW,
            height: winH,
            position: {
                my: "center",
                at: "center",
                of: window
            },
            buttons:                 
                {
                    'Close': function() {
                       //do something
                       $(this).dialog('close');
                    },
                    
                    
                
                   
                  
                   'Print': function(){
                	
                	  var printDialog = $(this).dialog().clone();
                	  $(titleGroup).find("h1.article-title").css('font-size', '28px');
                	  $(titleGroup).prependTo(printDialog).end();                	  
          			  $(journalCopyright).css('display', 'block').appendTo(printDialog).end();
          			  $(printDialog).find("a").removeAttr("href");
				
                	   $(printDialog).printElement(
                				
                			   
                	            {pageTitle:'',
                	               
                	                printBodyOptions:
                	                {
                	                styleToAdd:'width:auto;margin:15px;background-color:#ffffff !important;}',
                	                classNameToAdd : 'printVersion'
                	                },
                	               
                	                        
                	       
                	                            		 leaveOpen:true,
                	                 	                printMode:'popup'}
        
                    
                	   );
                

                	  
                       
                    },
                  
                  
                  },
        
            open: function (event, ui) {
            	

                $('.ui-widget-overlay').bind('click', function () { $(this).siblings('.ui-dialog').find('.ui-dialog-content').dialog('close');});
               
              
             
                
             $(this).focus()
              $(this).scrollTop(0);
            }
        });


        $("a[class='jOpener']").click(function (event) {
            var nameof = $(this).attr("name");
            $(".jModal[name=" + nameof + "]").dialog('open');
          
        });

        $("div[class='.jModal']").attr("style", "display:block;");
    });


              </script>
              





    <!-- Begin comScore Tag -->
<script>
var _comscore = _comscore || [];
_comscore.push({ c1: "2", c2: "9216157" });
(function() {
var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true;
s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js";
el.parentNode.insertBefore(s, el);
})();
</script>
<noscript>
<img src="http://b.scorecardresearch.com/p?c1=2&c2=9216157&cv=2.0&cj=1" />
</noscript>
<!-- End comScore Tag -->
	
		
		
			<!-- Begin EHS Head Tag -->
<script type="text/javascript">
//<![CDATA[
// Please remove % signs when replacing the value
// ehs_zone and all other values should be lower case
// If you are not using any of the key-values please leave them as null
var ehs_zone = "issue_content";
var ehs_kv = new Array();
ehs_kv.push("iprof=md;");
ehs_kv.push("ims1=f9;");
ehs_kv.push("ims2=null;");
ehs_kv.push("ims3=null;");
ehs_kv.push("rprof=null;");
ehs_kv.push("rms1=null;");
ehs_kv.push("rss1=null;");
ehs_kv.push("cdis=infectious_disease;"); // Discipline 
ehs_kv.push("ctop=influenza;"); // Topic
ehs_kv.push(""); // Gender
ehs_kv.push(""); // Population
ehs_kv.push("cfoc=treatment;"); // Focus
ehs_kv.push("ctyp=articles;"); // Type

// DO NOT CHANGE ANYTHING BELOW
var ehs_site = "ehs.pro.aafp.afp";
var ehs_inter=1;
var ehs_ismobile=0;
var ehs_puid=AAFP.components.content.EHSAds.getEHSGuid();

ehs_protocol = (document.location.protocol == "https:") ? "https://" : "http://";
if (ehs_protocol == "https://") ehs_kv.push("ssl=1;");

var ehs_tagsrc=ehs_protocol+'ads.ehealthcaresolutions.com/tag/';
document.write('<scr'+'ipt type="text/javascript" src="'+ehs_tagsrc+'"></scr'+'ipt>');
//]]>
</script>
<!-- End EHS Head Tag -->
		
	

	
		
			
				
				
					<!-- Begin EHS Body Tag -->

<div class="leaderboardAd adleaderboard">

		<div class="leaderboardAdContainer">
			
			<a href="http://www.aafp.org/journals/afp/advertisers/rates-policies/online-policies.html" class="advert-title"  target="_blank">Advertisement</a>
			<br>
				<script type="text/javascript">
				windowBigEnoughForBanner();
				function windowBigEnoughForBanner() {
					var w;
					var h;
					if (window.innerWidth) { //if browser supports window.innerWidth
						w = window.innerWidth;
						h = window.innerHeight;
					} else if (document.all) {//else if browser supports document.all (IE 4+)
						w = document.body.clientWidth;
						h = document.body.clientHeight;
					}
				
					if( w > 767)
					{
				 		EHS_AD("t", "r", "728x90,468x60"); 
					}
				}
				</script>
		</div>
</div>




<!-- End EHS Body Tag -->

				
			
		
		
	



 <script type="text/javascript" src="http://aafp.org/journals/afp.header.js"></script>





        
        <div role="main" id="main">


		<script> 
	var accTyp = "OPEN";  
	var metaRestrict = "false";
	</script>
	 

	<section id="content">

		<div class="bucket wide">

			<div class="block eight-column wide drop-shadow no-margin">

				<div class="white-background full-article">
				
				 

<!-- For QA 

-->

                     <?xml version="1.0" encoding="ISO-8859-1"?><div xmlns:xlink="http://www.w3.org/1999/xlink" class="articleContent"><div class="jpt"><div class="" style="padding: 0 10px 6px 10px"><p style="text-align:right" class="tocLink"><a style="font-size:12px;" href="&#10;                                  /afp/2000/1201/&#10;                              ">Dec 1, 2000 Table of Contents
                          </a></p><div class="titleGroup"><h1 class="article-title">Updated Treatment for Influenza A and B</h1></div><hr class="jptHide" style="color:#444444;background-color:#444444;border-color:#444444;"/><script>
                          $(document).ready(function(){
                          var refLink = window.location;
                          $('a.loginLink').attr('href','http://www.aafp.org/cgi-bin/lg.pl?redirect=' + refLink);
                          $('a.buyLink').attr('href','https://nf.aafp.org/Shop/single-issue-cme/' + buyName);
                          });
                      </script><h4 class="jptLog"><span class="fa fa-key fa-3x pull-left"><span style="font-size:0px;"><br/></span></span><span>
                              FREE PREVIEW <a href="" class="loginLink">Log in</a> or <a href="" class="buyLink">buy this issue</a> to read the full article. AAFP members and paid subscribers get free access to all articles. <a href="http://www.aafp.org/journals/afp/subscriptions/rates.html">Subscribe now</a>.
                          </span></h4><h4 class="jptDeny"><span class="fa fa-key fa-3x pull-left"><span style="font-size:0px;"><br/></span></span><span class="">
                              FREE PREVIEW <a href="http://www.aafp.org/journals/afp/subscriptions/rates.html">Subscribe</a> or <a href="" class="buyLink">buy this issue</a>. AAFP members and paid subscribers get free access to all articles.
                          </span></h4></div></div><div class="padding-left padding-right"><p class="byline no-margin">NORMAN J. MONTALTO, D.O., KIMBERLY D. GUM, PHARM.D., and JEFFREY V. ASHLEY, M.D., Robert C. Byrd Health Sciences Center of West Virginia University/Charleston Division, and Charleston Area Medical Center, Charleston, West Virginia</p><p class="self-citation"><i>Am Fam Physician.</i> 2000 Dec 1;62(11):2467-2476.</p><div style="display:none;"><div id="floatNavLinks"><ul class="bold"><li><a class="floater" href="#abstract" alt="Abstract">
                                Abstract
                            </a></li><li><a class="floater" href="#sec-1">Diagnosis of Influenza</a></li><li><a class="floater" href="#sec-2">Amantadine and Symmetrel</a></li><li><a class="floater" href="#sec-3">Neuraminidase Inhibitors</a></li><li><a class="floater" href="#sec-4">Final Comment</a></li><li><a class="floater" href="#ref-list-1">References</a></li></ul></div></div><div class="noPrint articleSections"><h3>Article Sections</h3><ul><li><a href="#abstract" alt="Abstract">
                                    Abstract
                                </a></li><li><a href="#sec-1">Diagnosis of Influenza</a></li><li><a href="#sec-2">Amantadine and Symmetrel</a></li><li><a href="#sec-3">Neuraminidase Inhibitors</a></li><li><a href="#sec-4">Final Comment</a></li><li><a href="#ref-list-1">References</a></li></ul></div></div><div class="padding-left padding-right"><div class="abstract" id="abstract">
<p>Influenza causes significant morbidity and mortality and is responsible for considerable medical expenditures. Vaccination is the most effective public health measure to combat this illness. Amantadine and rimantadine are older antiviral agents that have been important adjuncts in the prevention and treatment of influenza A outbreaks. Zanamivir and oseltamivir are newer agents indicated for the treatment of both influenza A and B. For antiviral agents to be effective, they must be used within 48 hours of the onset of influenza symptoms. Antiviral agents reduce the duration of fever and illness by one to two and one-half days and also reduce the severity of some symptoms. Use of amantadine or rimantadine is appropriate if influenza virus A is known to be the predominant agent in a particular year or location. Data need to be evaluated on the development of resistance and use of the newer antiviral agents in geriatric patients, high-risk patients and children. For optimal use of antiviral agents, patients with influenza symptoms must present early, and family physicians must accurately and rapidly diagnose the illness.</p></div>
<p>Influenza is a significant public health burden. In 1997, influenza and pneumonia were the sixth leading causes of death in the United States.<a class="superscript" href="#afp20001201p2467-b1">1</a> Over the past 25 years, approximately 20,000 deaths per year have been attributed to influenza in this country alone. The economic cost of influenza is estimated at $3 to $5 billion annually.<a class="superscript" href="#afp20001201p2467-b2">2</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b3">3</a></p>
<p>The prevention of influenza is best accomplished with a broad-based immunization program. Patients at highest risk should be given priority to receive influenza vaccine <span class="italic">(<a href="#afp20001201p2467-t1">Table 1</a>)</span>. <span class="italic"><a class="superscript" href="#afp20001201p2467-b4">4</a></span></p>
<p>Treatment of influenza with antiviral agents complements, but is not a substitute for, an extensive and effective vaccination program. Currently available antiviral agents include amantadine (Symmetrel) and rimantadine (Flum1p2467-b4">4</a></span></p>
<p>Treatment of influenza with antiviral agents complements, but is not a substitute for, an extensive and effective vaccination program. Currently available antiviraadine), which are active against influenza virus A, and two newer products, zanamivir (Relenza) and oseltamivir (Tamiflu), which have activity against influenza viral types A and B.</p>

<div class="printTable">
<span class="table-label">TABLE 1</span>

<h4 class="table-title">Recommendations for the Administration of Influenza Vaccine: Categories and Specific Indications</h4>
<table class="no-mobile-table">

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Age</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Persons six months or older with an underlying medical condition (e.g., cardiac, pulmonary) who are at increased risk for complications of influenza or who required regular medical follow-up or hospitalization during the preceding year (see medical conditions below)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Persons 50 years or older</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><pon during the preceding year (see medical conditions below)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Persons 50 years or older</p></td></tr>
<t class="Tabledata">Any person six months or older to reduce the chance of influenza infection</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Occupations</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Physicians, nurses and other personnel in hospital and outpatient care settings, including emergency response workers</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Employees of health care facilities (e.g., nursing homes, chronic care facilities) who have contact with residents</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Persons who provide home care to people in high-risk groups</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Medical conditions</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Alcoholism and alcoholic cirrhosis</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Long-term aspirin therapy in children and teenagers (6 months to 18 years of age) who may be at risk for Reye's syndrome after influenza virus infection</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chronic cardiovascular disorders in adults and chiteenagers (6 months to 18 years of age) who may be at risk for Reye's ldren</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Hemoglobinopathies</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Immunocompromised conditions (e.g., congenital immunodeficiency, malignancy, human immunodeficiency virus infection, organ transplantation, immunosuppressive therapy)*</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chronic metabolic diseases (e.g., diabetes)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chronic pulmonary diseases, including asthma and chronic obstructive pulmonary disease</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chronic renal dysfunction</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Pregnancy beyond 14 weeks of gestation during the influenza season</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Pregnancy in women with medical conditions that increase their risk for complications from influenza, regardless of trimester</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Persons who can transmit influenza to high-risk individuals</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p cla/td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><ss="Tabledata">Household members (including children) in close contact with persons who are at high risk for influenza</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Residents of nursing homes and other chronic care facilities, regardless of age, who have chronic medical conditions</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">*&#8212;Vaccination ideally should occur about two weeks before chemotherapy or immunosuppressive therapy is started. If a patient is vaccinated during or within two weeks before the initiation of immunosuppressive therapy, influenza vaccine should be given again about three months after treatment ends</span>.</p></div><div class="fn"><p class="fn"><span class="italic">Information from Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49(RR-3):1&#8211;38</span>.</p></div></div></div><div class="table-format" id="afp20001201p2467-t1"><div class="calltoactionbox"><div class="jDialog highlights"><div class="container secondary"><div class="jDialogPrintHide"><h4>TABLE 1
                                                   
                                              Recommendations for the Administration of Influenza Vaccine: Categories and Specific Indications</h4><p><a class="jOpener" name="afp20001201pde"><h4>TABLE 1
                                                   
   2467-t1">
                                              View Table
                                          </a></p></div><div class="jModal" title="TABLE 1" name="afp20001201p2467-t1"><div class="tableModal">
<span class="table-label">TABLE 1</span>

<h4 class="table-title">Recommendations for the Administration of Influenza Vaccine: Categories and Specific Indications</h4>
<table class="no-mobile-table">

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Age</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Persons six months or older with an underlying medical condition (e.g., cardiac, pulmonary) who are at increased risk for complications of influenza or who required regular medical follow-up or hospitalization during the preceding year (see medical conditions below)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Persons 50 years or older</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Any person six months or older to reduce the chance of influenza infection</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Occupations</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Physicians, nurses and other personnel in hospital and outpatip" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span claent care settings, including emergency response workers</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Employees of health care facilities (e.g., nursing homes, chronic care facilities) who have contact with residents</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Persons who provide home care to people in high-risk groups</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Medical conditions</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Alcoholism and alcoholic cirrhosis</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Long-term aspirin therapy in children and teenagers (6 months to 18 years of age) who may be at risk for Reye's syndrome after influenza virus infection</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chronic cardiovascular disorders in adults and children</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Hemoglobinopathies</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Immunocompromised conditions (e.g., congenital immunodeficiency, malignancy, human immunodeficiency virus infection, organ transplantation, immunosuppressivhies</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p cle therapy)*</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chronic metabolic diseases (e.g., diabetes)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chronic pulmonary diseases, including asthma and chronic obstructive pulmonary disease</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chronic renal dysfunction</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Pregnancy beyond 14 weeks of gestation during the influenza season</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Pregnancy in women with medical conditions that increase their risk for complications from influenza, regardless of trimester</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Persons who can transmit influenza to high-risk individuals</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Household members (including children) in close contact with persons who are at high risk for influenza</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Residents of nursing homes and other chronic care facilities, regardless of age, who have chronic medical conditions</p></td></tr></table>
<hr class="table-enza</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" alignfoot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">*&#8212;Vaccination ideally should occur about two weeks before chemotherapy or immunosuppressive therapy is started. If a patient is vaccinated during or within two weeks before the initiation of immunosuppressive therapy, influenza vaccine should be given again about three months after treatment ends</span>.</p></div><div class="fn"><p class="fn"><span class="italic">Information from Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49(RR-3):1&#8211;38</span>.</p></div></div></div></div></div></div></div></div><div class="jSection" id="sec-1">
<h2>Diagnosis of Influenza</h2><div class="mjToggle noPrint"><div class="mjHeader noPrint"><span style="margin:5px;">Jump to section +</span></div><div class="mjContent noPrint"><ul><li><a href="#abstract" alt="Abstract">
                                    Abstract
                                </a></li><li><a href="#sec-1">Diagnosis of Influenza</a></li><li><a href="#sec-2">Amantadine and Symmetrel</a></li><li><a href="#sec-3">Neuraminidase Inhibitors</a></li><li><a href="#sec-4">Final Comment</a></li><li><a href="#ref-list-1">References</a></li></ul></div></div>
<p>Influenza must be distinguished from infection with the many viruses that cause the common cold, as both conditions occur primarily in the upper reli><a href="#sec-4">Final Comment</a></li><li><a href="#ref-list-1">Referencesspiratory tract <span class="italic">(<a href="#afp20001201p2467-t2">Table 2</a>)</span>.<a class="superscript" href="#afp20001201p2467-b5">5</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b6">6</a> Bacterial infections can mimic influenza or occur as a complication of influenza virus infection. Antiviral agents have no effect on bacterial infections and do not prevent their complications.</p>
<div class="printTable">
<span class="table-label">TABLE 2</span>

<h4 class="table-title">Comparing the Symptoms of Influenza and the Common Cold</h4>
<table class="no-mobile-table">
<thead>
<tr>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Symptoms</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Influenza</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Common cold</span></span></th></tr></thead>

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Onset</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Abrupt</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">More gradual</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Fever</p></td>
<td valign="to"left"><p class="Tabledata">Abrupt</p></td>
<td valign="top" colspan="p" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common: 37.7 to 40°C (100 to 104°F)</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Uncommon or an increase of only about 0.5°C (1°F)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Myalgia</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Severe, common</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Uncommon</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Arthralgia</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Severe, common</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Uncommon</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Anorexia</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Uncommon</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Headache</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Severe, common</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Mild, uncommon</p></td></tr>
<tr>
<td valign="top" colspan="1">Headache</p></td>
<td valign="top" colspan="1" rowspan="1" align="left">" rowspan="1" align="left"><p class="Tabledata">Cough (dry)</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common, severe</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Mild to moderate</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Malaise</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Severe</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Mild</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Fatigue, weakness</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">More common, lasting 2 to 3 weeks</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Very mild, short lasting</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chest discomfort</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common, severe</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Mild to moderate</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Stuffy nose</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Occasional</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p c
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="lass="Tabledata">Common</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Sneezing</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Occasional</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Sore throat</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Occasional</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">Information from Dolin R. Infectious disease. In: Fauci AS, et al., eds. Harrison's Principles of internal medicine. 14th ed. New York: McGraw-Hill, Health Professions Division, 1998:1112&#8211;6, and Is it a cold or the flu? Retrieved October 9, 2000, from: <a href="http://www.niaid.nih.gov/publications/cold/sick.htm">http://www.niaid.nih.gov/publications/cold/sick.htm</a></span>.</p></div></div></div><div class="table-format" id="afp20001201p2467-t2"><div class="calltoactionbox"><div class="jDialog highlights"><div class="container secondary"><div class="jDialogPrintHide"><h4>TABLE 2
                                                   
                                              Comparing the Symptoms of Influenzalltoactionbox"><div class="jDialog highlights"><div class="container secondary and the Common Cold</h4><p><a class="jOpener" name="afp20001201p2467-t2">
                                              View Table
                                          </a></p></div><div class="jModal" title="TABLE 2" name="afp20001201p2467-t2"><div class="tableModal">
<span class="table-label">TABLE 2</span>

<h4 class="table-title">Comparing the Symptoms of Influenza and the Common Cold</h4>
<table class="no-mobile-table">
<thead>
<tr>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Symptoms</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Influenza</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Common cold</span></span></th></tr></thead>

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Onset</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Abrupt</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">More gradual</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Fever</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common: 37.7 to 40°C (100 to 104°F)</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Taban="1" rowspan="1" align="left"><p class="Tabledata">Fever</p></td>
<td valign="ledata">Uncommon or an increase of only about 0.5°C (1°F)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Myalgia</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Severe, common</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Uncommon</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Arthralgia</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Severe, common</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Uncommon</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Anorexia</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Uncommon</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Headache</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Severe, common</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Mild, uncommon</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Cough (dry)</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common, severe</p></td>
<td val class="Tabledata">Mild, uncommon</p></td></tr>
<tr>
<td valign="top" coign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Mild to moderate</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Malaise</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Severe</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Mild</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Fatigue, weakness</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">More common, lasting 2 to 3 weeks</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Very mild, short lasting</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Chest discomfort</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common, severe</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Mild to moderate</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Stuffy nose</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Occasional</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Sneezing</p></td>
<td valign="top" colspan="1" rowspan="1">Occasional</p></td>
<td valign="top" colspan="1" rowspan="1" align="" align="left"><p class="Tabledata">Occasional</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Sore throat</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Occasional</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Common</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">Information from Dolin R. Infectious disease. In: Fauci AS, et al., eds. Harrison's Principles of internal medicine. 14th ed. New York: McGraw-Hill, Health Professions Division, 1998:1112&#8211;6, and Is it a cold or the flu? Retrieved October 9, 2000, from: <a href="http://www.niaid.nih.gov/publications/cold/sick.htm">http://www.niaid.nih.gov/publications/cold/sick.htm</a></span>.</p></div></div></div></div></div></div></div></div><p>A history consistent with influenza symptoms and a knowledge of the presence of influenza in the community increase the likelihood of accurate diagnosis. Various Web sites provide up-to-date information on influenza in specific cities, states and regions <span class="italic">(<a href="#afp20001201p2467-t3">Table 3</a>)</span>. In addition, several rapid tests are available to confirm the diagnosis of influenza A or B and may be helpful in some situations. Using thes in specific cities, states and regions <span class="italic">(<a href=e aids, physicians can monitor the influenza type and its prevalence in their area, diagnose influenza more accurately and consider treatment options more carefully. In 1999&#8211;2000, for example, the peaks of widespread influenza A activity varied based on location. Because influenza B activity was not widespread, use of the less expensive antiviral agents (amantadine and rimantadine) would have been appropriate.</p>
<div class="printTable">
<span class="table-label">TABLE 3</span>

<h4 class="table-title">Internet Resources for Influenza Prevention and Control</h4>
<table class="no-mobile-table">

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">CDC Influenza Information: <a href="http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm">http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">National Institute of Allergy and Infectious Diseases: <a href="http://www.niaid.nih.gov">http://www.niaid.nih.gov</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">World Health Organization: <a href="http://www.who.int/health-topics/influenza.htm">http://www.who.int/health-topics/influenza.htm</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">FluNet: <a href="http://www.who.int/flunet">http://www.who.int/flunet</a></p></td></tr>
<tpics/influenza.htm">http://www.who.int/health-topics/influenza.htm</a>r>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">U.S. Department of Health and Human Services: <a href="http://www.dhhs.gov">http://www.dhhs.gov</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">American Lung Association: <a href="http://www.lungusa.org/diseases/c&amp;fguide/lungcolds_flu.html">http://www.lungusa.org/diseases/c&amp;amp;fguide/lungcolds_flu.html</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">National Foundation for Infectious Disease: <a href="http://www.nfid.org/library/influenza">http://www.nfid.org/library/influenza</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Consumer health information from sources such as John Hopkins and Harvard Medical School: <a href="http://www.intelihealth.com">http://www.intelihealth.com</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">ZymeTx, Inc.: <a href="http://www.fluwatch.com">http://www.fluwatch.com</a></p></td></tr></table></div><div class="table-format" id="afp20001201p2467-t3"><div class="calltoactionbox"><div class="jDialog highlights"><div class="container secondary"><div class="jDialogPrintHide"><h4>TABLE 3
                                                   
                                              Internet Resources for Influenza Preventiononbox"><div class="jDialog highlights"><div class="container secondary"><div c and Control</h4><p><a class="jOpener" name="afp20001201p2467-t3">
                                              View Table
                                          </a></p></div><div class="jModal" title="TABLE 3" name="afp20001201p2467-t3"><div class="tableModal">
<span class="table-label">TABLE 3</span>

<h4 class="table-title">Internet Resources for Influenza Prevention and Control</h4>
<table class="no-mobile-table">

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">CDC Influenza Information: <a href="http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm">http://www.cdc.gov/ncidod/diseases/flu/fluvirus.htm</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">National Institute of Allergy and Infectious Diseases: <a href="http://www.niaid.nih.gov">http://www.niaid.nih.gov</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">World Health Organization: <a href="http://www.who.int/health-topics/influenza.htm">http://www.who.int/health-topics/influenza.htm</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">FluNet: <a href="http://www.who.int/flunet">http://www.who.int/flunet</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">U.S. Department of Health and Human Services: <a href="http://www.dhhs.gov">http://www.dhhs.gov<a href="http://www.who.int/flunet">http://www.who.int/flunet</a></p></td></tr/a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">American Lung Association: <a href="http://www.lungusa.org/diseases/c&amp;fguide/lungcolds_flu.html">http://www.lungusa.org/diseases/c&amp;amp;fguide/lungcolds_flu.html</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">National Foundation for Infectious Disease: <a href="http://www.nfid.org/library/influenza">http://www.nfid.org/library/influenza</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Consumer health information from sources such as John Hopkins and Harvard Medical School: <a href="http://www.intelihealth.com">http://www.intelihealth.com</a></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">ZymeTx, Inc.: <a href="http://www.fluwatch.com">http://www.fluwatch.com</a></p></td></tr></table></div></div></div></div></div></div></div>
<div class="jSection" id="sec-2">
<h2>Amantadine and Symmetrel</h2><div class="mjToggle noPrint"><div class="mjHeader noPrint"><span style="margin:5px;">Jump to section +</span></div><div class="mjContent noPrint"><ul><li><a href="#abstract" alt="Abstract">
                                    Abstract
                                </a></li><li><a href="#sec-1">Diagnosis of Influenza</a></li><li><a href="#sec-2">Amantadine and Symmetrel</a></li><li><a href="#snt"><ul><li><a href="#abstract" alt="Abstract">
                              ec-3">Neuraminidase Inhibitors</a></li><li><a href="#sec-4">Final Comment</a></li><li><a href="#ref-list-1">References</a></li></ul></div></div>
<p>Amantadine was the first antiviral agent approved by the U.S. Food and Drug Administration (FDA) for the prophylaxis (1966) and treatment (1976) of influenza A in adults and in children one year and older. In 1993, the FDA approved rimantadine for the prevention and treatment of influenza A in adults, but for prophylaxis only in children more than one year of age.<a class="superscript" href="#afp20001201p2467-b4">4</a></p>
<p>The mechanism by which amantadine and rimantadine exert their antiviral effect is not clearly understood. These antiviral agents are thought to inhibit the M<sub>2</sub> ion channel (present only on influenza virus A), thereby preventing viral uncoating.<a class="superscript" href="#afp20001201p2467-b7">7</a></p>

<p>Amantadine and rimantadine are inexpensive and effective. However, use is limited by their lack of activity against influenza virus B.<a class="superscript" href="#afp20001201p2467-b4">4</a>  The advantages and disadvantages of these antiviral agents are listed in <span class="italic"><a href="#afp20001201p2467-t4">Table 4</a></span>,<a class="superscript" href="#afp20001201p2467-b4">4</a>  and their similarities and differences are presented in <span class="italic"><a href="#afp20001201p2467-t5">Table 5</a></span>.<a class="superscript" href="#afp20001201p2467-t4">Table 4</a></span>,<a class="superscript" href="#afp20001201p1p2467-b4">4</a>  Age-based dosages are provided in <span class="italic"><a href="#afp20001201p2467-t6">Table 6</a></span>.<a class="superscript" href="#afp20001201p2467-b4">4</a></p><div class="printTable">
<span class="table-label">TABLE 4</span>

<h4 class="table-title">Advantages and Disadvantages of Amantadine (Symmetrel) and Rimantadine (Flumadine)</h4>
<table class="no-mobile-table">

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Advantages</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Indicated for prophylaxis in adults and in children more than 1 year of age</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Amantadine can be used as treatment in children 1 year and older.</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Various formulations (tablet, capsule, syrup)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Reduce duration of uncomplicated illness</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Less costly than newer antiviral agents</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Disadvantages</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><edata">Less costly than newer antiviral agents</p></td></tr>
<tr>
<td vp class="Tabledata">Effective only against influenza virus A</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Central nervous system and gastrointestinal side effects</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Dosage reductions necessary in patients with hepatic or renal insufficiency</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Effective only when given within 48 hours of onset of symptoms</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Higher risk of drug resistance</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">Information from Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49(RR-3):1&#8211;38</span>.</p></div></div></div><div class="table-format" id="afp20001201p2467-t4"><div class="calltoactionbox"><div class="jDialog highlights"><div class="container secondary"><div class="jDialogPrintHide"><h4>TABLE 4
                                                   
                                              Advantages and Disadvantages of Amantadine (Symmetrel) and Rimantadine (Flumadine)</h4><p><a class="jOpener" name="afp20001201p2467-t4">
                                                                       
                                                    View Table
                                          </a></p></div><div class="jModal" title="TABLE 4" name="afp20001201p2467-t4"><div class="tableModal">
<span class="table-label">TABLE 4</span>

<h4 class="table-title">Advantages and Disadvantages of Amantadine (Symmetrel) and Rimantadine (Flumadine)</h4>
<table class="no-mobile-table">

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Advantages</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Indicated for prophylaxis in adults and in children more than 1 year of age</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Amantadine can be used as treatment in children 1 year and older.</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Various formulations (tablet, capsule, syrup)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Reduce duration of uncomplicated illness</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Less costly than newer antiviral agents</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Disadvantages</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Effective only against nts</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align=influenza virus A</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Central nervous system and gastrointestinal side effects</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Dosage reductions necessary in patients with hepatic or renal insufficiency</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Effective only when given within 48 hours of onset of symptoms</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Higher risk of drug resistance</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">Information from Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49(RR-3):1&#8211;38</span>.</p></div></div></div></div></div></div></div></div><div class="printTable">
<span class="table-label">TABLE 5</span>

<h4 class="table-title">Comparison of Amantadine (Symmetrel) and Rimantadine (Flumadine)</h4>
<table class="no-mobile-table">
<thead>
<tr>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Characteristic</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Amantadine</span><m" class="th" colspan="1" rowspan="1" align="left"><span class="italic/span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Rimantadine</span></span></th></tr></thead>

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Metabolism and elimination</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Renal clearance by filtration and tubular secretion</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Hepatic metabolism and renal excretion</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Side effects</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Commonly has CNS and gastrointestinal side effects</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Less likely to have CNS and gastrointestinal side effects</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Drug interactions</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">CNS stimulants, antihistamines, anticholinergic agents</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Not clinically significant</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Pregnancy category and breast-feeding recommendation</p></td>
<td valign=p" colspan="1" rowspan="1" align="left"><p class="Tabledata">Not clinically signific"top" colspan="1" rowspan="1" align="left"><p class="Tabledata">C; not recommended for use in breast-feeding mothers</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">C; not recommended for use in breast-feeding mothers</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Cost for 5-day treatment course*</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">$9.82 (3.48 to 6.74)</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">$18.87</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">CNS = central nervous system</span>.</p></div><div class="fn"><p class="fn"><span class="italic">*&#8212;Estimated cost to the pharmacist based on average wholesale prices for treatment in adults as provided in Red book. Montvale, N.J.: Medical Economics Data, 2000. Cost to the patient will be higher, depending on prescription filling fee</span>.</p></div><div class="fn"><p class="fn"><span class="italic">Information from Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49(RR-3):1&#8211;38</span>.</p></div></div></div><div class="table-format" id="afp20001201p2467-t5"><div class="calltoactionbox"><div class="jDialog highlights"><div class="container secondary Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49(RR-3"><div class="jDialogPrintHide"><h4>TABLE 5
                                                   
                                              Comparison of Amantadine (Symmetrel) and Rimantadine (Flumadine)</h4><p><a class="jOpener" name="afp20001201p2467-t5">
                                              View Table
                                          </a></p></div><div class="jModal" title="TABLE 5" name="afp20001201p2467-t5"><div class="tableModal">
<span class="table-label">TABLE 5</span>

<h4 class="table-title">Comparison of Amantadine (Symmetrel) and Rimantadine (Flumadine)</h4>
<table class="no-mobile-table">
<thead>
<tr>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Characteristic</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Amantadine</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Rimantadine</span></span></th></tr></thead>

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Metabolism and elimination</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Renal clearance by filtration and tubular secretion</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Hepatic metabolism and renal excretion</p></td></tlign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Rer>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Side effects</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Commonly has CNS and gastrointestinal side effects</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Less likely to have CNS and gastrointestinal side effects</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Drug interactions</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">CNS stimulants, antihistamines, anticholinergic agents</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Not clinically significant</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Pregnancy category and breast-feeding recommendation</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">C; not recommended for use in breast-feeding mothers</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">C; not recommended for use in breast-feeding mothers</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Cost for 5-day treatment course*</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">$9.82 (3.48 to 6.74)</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><an="1" rowspan="1" align="left"><p class="Tabledata">Cost for 5-day treatment p class="Tabledata">$18.87</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">CNS = central nervous system</span>.</p></div><div class="fn"><p class="fn"><span class="italic">*&#8212;Estimated cost to the pharmacist based on average wholesale prices for treatment in adults as provided in Red book. Montvale, N.J.: Medical Economics Data, 2000. Cost to the patient will be higher, depending on prescription filling fee</span>.</p></div><div class="fn"><p class="fn"><span class="italic">Information from Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2000;49(RR-3):1&#8211;38</span>.</p></div></div></div></div></div></div></div></div><div class="printTable">
<span class="table-label">TABLE 6</span>

<h4 class="table-title">Dosages of Amantadine (Symmetrel) and Rimantadine (Flumadine)</h4>
<table class="no-mobile-table">
<thead>
<tr>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Indication</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Patient age (years)</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Amantadine*</span></span></th>
<th valign="bottom" class="th"t"><span class="italic"><span class="italic">Patient age (years)</span colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Rimantadine</span>&#8224;</span></th></tr></thead>

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Treatment</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">1 to 9</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">5 mg per kg per day, up to 150 mg given in two divided doses&#8225;</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">NA</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">10 to 13</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily§</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">NA</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">14 to 64</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1twice daily</p></td>
<td valign="top" colspan="1" rowspan="1" align="le" align="left"><p class="Tabledata">&#8805;65</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">&#8804;100 mg twice daily</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 or 200 mg per day&#8741;</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Prophylaxis</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">1 to 9</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">5 mg per kg per day, up to 150 mg given in two divided doses&#8225;</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">5 mg per kg per day, up to 150 mg given in two divided doses&#8225;</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">10 to 13</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily§</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily§</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">14 to 64</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily<p" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign=/p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">&#8805;65</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">&#8804;100 mg twice daily</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 or 200 mg twice daily&#8741;</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">NA = not applicable</span>.</p></div><div class="fn"><p class="fn"><span class="italic">*&#8212;Consult drug package insert for dosage recommendations when administering amantadine to patients with a creatinine clearance of 50 mL per minute per 1.73 m</span><span class="italic"><a href="#afp20001201p2467-b2">2</a> or less</span>.</p></div><div class="fn"><p class="fn"><span class="italic">&#8224;&#8212;A reduction in dosage to 100 mg per day of rimantadine is recommended in patients who have severe hepatic dysfunction or a creatinine clearance of 10 mL per minute or less. Other patients with less severe hepatic or renal dysfunction who are taking 100 mg per day of rimantadine should be observed closely, and the dosage should be reduced or the drug discontinued if necessary</span>.</p></div><div class="fn"><p class="fn">&#8225;<span class="italic">&#8212;5 mg per kg of amantadine or rimantadine syrup = 1 teaspoon per 10 kg (22 lb)</span>.</p></div><div class="fn"><p class="fn">§<span class="italic">&#8212;Children 10 years and older who weigh less than 40 kg (88 lb) should be given amantadine or rimantadine in a dosage of 5 mg per kg per day</span>.</p></div><div class="fn"><p class="fn"><span class="italic">&#8741;&#8212;Elderly nursing home residents should be given rimantadine in who weigh less than 40 kg (88 lb) should be given amantadine or rimantadine in a dosage of 5 mg per  a dosage of only 100 mg per day. A dosage reduction to 100 mg per day should be considered in all patients 65 years and older if they have side effects when taking rimantadine in a dosage of 200 mg per day</span>.</p></div><div class="fn"><p class="fn"><span class="italic">Adapted from Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 2000;49(RR-03):1&#8211;38</span>.</p></div></div></div><div class="table-format" id="afp20001201p2467-t6"><div class="calltoactionbox"><div class="jDialog highlights"><div class="container secondary"><div class="jDialogPrintHide"><h4>TABLE 6
                                                   
                                              Dosages of Amantadine (Symmetrel) and Rimantadine (Flumadine)</h4><p><a class="jOpener" name="afp20001201p2467-t6">
                                              View Table
                                   
                                                            </a></p></div><div class="jModal" title="TABLE 6" name="afp20001201p2467-t6"><div class="tableModal">
<span class="table-label">TABLE 6</span>

<h4 class="table-title">Dosages of Amantadine (Symmetrel) and Rimantadine (Flumadine)</h4>
<table class="no-mobile-table">
<thead>
<tr>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Indication</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Patient age (years)</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Amantadine*</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Rimantadine</span>&#8224;</span></th></tr></thead>

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Treatment</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">1 to 9</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">5 mg per kg per day, up to 150 mg given in two divided doses&#8225;</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">NA</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align=ivided doses&#8225;</p></td>
<td valign="top" colspan="1" rowspan="1" al"left"><p class="Tabledata">10 to 13</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily§</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">NA</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">14 to 64</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">&#8805;65</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">&#8804;100 mg twice daily</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 or 200 mg per day&#8741;</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Prophylaxis</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">1 to 9</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">5 mg per kg per day, up to 150 mg given in two divided doses&#8225;</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledatas="Tabledata">1 to 9</p></td>
<td valign="top" colspan="1" rowspan="1" ">5 mg per kg per day, up to 150 mg given in two divided doses&#8225;</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">10 to 13</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily§</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily§</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">14 to 64</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 mg twice daily</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"/></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">&#8805;65</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">&#8804;100 mg twice daily</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">100 or 200 mg twice daily&#8741;</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">NA = not applicable</span>.</p></div><div class="fn"><p class="fn"><spgn="left"><p class="Tabledata">100 or 200 mg twice daily&#8741;</p></td>an class="italic">*&#8212;Consult drug package insert for dosage recommendations when administering amantadine to patients with a creatinine clearance of 50 mL per minute per 1.73 m</span><span class="italic"><a href="#afp20001201p2467-b2">2</a> or less</span>.</p></div><div class="fn"><p class="fn"><span class="italic">&#8224;&#8212;A reduction in dosage to 100 mg per day of rimantadine is recommended in patients who have severe hepatic dysfunction or a creatinine clearance of 10 mL per minute or less. Other patients with less severe hepatic or renal dysfunction who are taking 100 mg per day of rimantadine should be observed closely, and the dosage should be reduced or the drug discontinued if necessary</span>.</p></div><div class="fn"><p class="fn">&#8225;<span class="italic">&#8212;5 mg per kg of amantadine or rimantadine syrup = 1 teaspoon per 10 kg (22 lb)</span>.</p></div><div class="fn"><p class="fn">§<span class="italic">&#8212;Children 10 years and older who weigh less than 40 kg (88 lb) should be given amantadine or rimantadine in a dosage of 5 mg per kg per day</span>.</p></div><div class="fn"><p class="fn"><span class="italic">&#8741;&#8212;Elderly nursing home residents should be given rimantadine in a dosage of only 100 mg per day. A dosage reduction to 100 mg per day should be considered in all patients 65 years and older if they have side effects when taking rimantadine in a dosage of 200 mg per day</span>.</p></ents should be given rimantadine in a dosage of only 100 mg per day. A dosage div><div class="fn"><p class="fn"><span class="italic">Adapted from Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morbid Mortal Wkly Rep 2000;49(RR-03):1&#8211;38</span>.</p></div></div></div></div></div></div></div></div></div>
<div class="jSection" id="sec-3">
<h2>Neuraminidase Inhibitors</h2><div class="mjToggle noPrint"><div class="mjHeader noPrint"><span style="margin:5px;">Jump to section +</span></div><div class="mjContent noPrint"><ul><li><a href="#abstract" alt="Abstract">
                                    Abstract
                                </a></li><li><a href="#sec-1">Diagnosis of Influenza</a></li><li><a href="#sec-2">Amantadine and Symmetrel</a></li><li><a href="#sec-3">Neuraminidase Inhibitors</a></li><li><a href="#sec-4">Final Comment</a></li><li><a href="#ref-list-1">References</a></li></ul></div></div>
<p>In 1999, the FDA approved zanamivir and oseltamivir for the treatment of uncomplicated acute influenza A or B in patients who have been symptomatic for less than 48 hours.<a class="superscript" href="#afp20001201p2467-b8">8</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b9">9</a> There is some evidence that these agents are also effective for prophylaxis, although they are not yet approved for this indication.</p>
<p>Zanamivir and oseltamivir are neuraminidase inhibitors. Neuraminidase is a viral-surfaceafp20001201p2467-b9">9</a> There is some evidence that these agents ar glycoprotein that is necessary for the replication of influenza viruses A and B. Neuraminidase activity permits the viruses to spread to other cells.<a class="superscript" href="#afp20001201p2467-b10">10</a> Neuraminidase inhibitors prevent viruses from budding (releasing) and spreading. They may also reduce the spread of influenza viruses throughout the respiratory tract and allow upper respiratory tract mucus to inactivate the viruses more easily.<a class="superscript" href="#afp20001201p2467-b11">11</a> They do not interfere with the antibody response to vaccine.<a class="superscript" href="#afp20001201p2467-b4">4</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b12">12</a>  The advantages and disadvantages of neuraminidase inhibitors are presented in <span class="italic"><a href="#afp20001201p2467-t7">Table 7</a></span>. Zanamivir and oseltamivir are compared in <span class="italic"><a href="#afp20001201p2467-t8">Table 8</a></span>.<a class="superscript" href="#afp20001201p2467-b8">8</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b9">9</a></p>
<div class="printTable">
<span class="table-label">TABLE 7</span>

<h4 class="table-title">Advantages and Disadvantages of Neuraminidase Inhibitors</h4>
<table class="no-mobile-table">

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Advantages</span></p></td></t/span>

<h4 class="table-title">Advantages and Disadvantages of Neuraminidase Ir>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Effective against influenza virus A and B</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Reduced duration and severity of selected symptoms</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">No central nervous system side effects</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Decreased incidence of influenza complications and antibiotic use</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Lower risk for emergence of drug resistance</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Disadvantages</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Effective only when treatment is initiated within 48 hours of the onset of symptoms</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Lack of data on use in geriatric, high-risk and pediatric patients</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">No data on use in patients with renal or hepatic dysfunction Cost</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Zanamivir (Relenza) not indicatetop" colspan="1" rowspan="1" align="left"><p class="Tabledata">No datad in children less than 7 years of age; oseltamivir (Tamiflu) not indicated in children less than 18 years of age</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Zanamivir generally not recommended in patients with underlying airway disease (asthma, chronic obstructive pulmonary disease); may cause allergic-like reactions</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Patient education required for use of inhaler in zanamivir therapy</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Not approved for prophylaxis</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Less clinical experience with these agents</p></td></tr></table></div><div class="table-format" id="afp20001201p2467-t7"><div class="calltoactionbox"><div class="jDialog highlights"><div class="container secondary"><div class="jDialogPrintHide"><h4>TABLE 7
                                                   
                                              Advantages and Disadvantages of Neuraminidase Inhibitors</h4><p><a class="jOpener" name="afp20001201p2467-t7">
                                              View Table
                                          </a></p></div><div class="jModal" title="TABLE 7" name="afp20001201p2467-t7"><div class="tableModal">
<span class="table-label">TABLE 7</span>

<h2467-t7">
                                              View Table
    4 class="table-title">Advantages and Disadvantages of Neuraminidase Inhibitors</h4>
<table class="no-mobile-table">

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Advantages</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Effective against influenza virus A and B</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Reduced duration and severity of selected symptoms</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">No central nervous system side effects</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Decreased incidence of influenza complications and antibiotic use</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Lower risk for emergence of drug resistance</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata"><span class="bold">Disadvantages</span></p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Effective only when treatment is initiated within 48 hours of the onset of symptoms</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Lack of data on use in geriatric, high-risk and pediatric patients</p></td></tr>
<tr>
<td valign="top" colsps initiated within 48 hours of the onset of symptoms</p></td></tr>
<tran="1" rowspan="1" align="left"><p class="Tabledata">No data on use in patients with renal or hepatic dysfunction Cost</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Zanamivir (Relenza) not indicated in children less than 7 years of age; oseltamivir (Tamiflu) not indicated in children less than 18 years of age</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Zanamivir generally not recommended in patients with underlying airway disease (asthma, chronic obstructive pulmonary disease); may cause allergic-like reactions</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Patient education required for use of inhaler in zanamivir therapy</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Not approved for prophylaxis</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Less clinical experience with these agents</p></td></tr></table></div></div></div></div></div></div><div class="printTable">
<span class="table-label">TABLE 8</span>

<h4 class="table-title">Comparison of Zanamivir (Relenza) and Oseltamivir (Tamiflu)</h4>
<table class="no-mobile-table">
<thead>
<tr>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Characteristic</span></span></th>
<th valign="botZanamivir (Relenza) and Oseltamivir (Tamiflu)</h4>
<table class="no-mobile-tatom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Zanamivir*</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Oseltamivir*</span></span></th></tr></thead>

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Age limit for use</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">7 years and older</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">18 years and older</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Route of administration</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Oral (inhalation)</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Oral (capsule)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Dosage</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">10 mg twice daily&#8224;</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">75 mg twice daily</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Precautions and warnings</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Not generally recommended in patients withice daily</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1"  asthma, COPD or other underlying airway disease; may cause bronchospasm and allergic-like reactions</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">A dosage reduction is recommended for patients with a creatinine clearance of less than 30 mL per minute (0.50 mL per second).</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Metabolism and elimination</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Renally excreted as unchanged drug Not a substrate or inhibitor of cytochrome P450 isoenzymes</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Converted to oseltamivir carboxylate primarily by hepatic esterases Not a substrate or inhibitor of cytochrome P450 isoenzymes</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Side effects</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Nasal and throat irritation, cough, headache; bronchospasm and decreased expiratory flow rate in patients with asthma or COPD</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Nausea and vomiting, which may be reduced by administration with food</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Drug interactions</p></td>
<td valign="top" colspan="1" rowspan="eft"><p class="Tabledata">Nausea and vomiting, which may be reduced by adminis1" align="left"><p class="Tabledata">Unlikely, but has not been studied completely</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Unlikely, but has not been studied completely</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Pregnancy category</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">C</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">C</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Cost for five-day treatment course&#8225;</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">$44.40</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">$53</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">COPD = chronic obstructive pulmonary disease</span>.</p></div><div class="fn"><p class="fn"><span class="italic">*&#8212;Neither zanamivir nor oseltamivir is approved for prophylaxis</span>.</p></div><div class="fn"><p class="fn">&#8224; <span class="italic">&#8212;Zanamivir is administered using a plastic device that is included in the medication package. Patients should be instructed on proper use of the device. Two inhalations (one 5-mg blister per inhalation for a total dose of 10 mg) are administered twice daily (apivir is administered using a plastic device that is included in the meproximately 12 hours apart) for five days. Two doses should be taken on the first day of treatment whenever possible, provided that there is at least two hours between doses. On subsequent days, doses should be taken about 12 hours apart (e.g., morning and evening) at approximately the same time each day</span>.</p></div><div class="fn"><p class="fn">&#8225;<span class="italic">&#8212;Estimated cost to the pharmacist based on average wholesale prices for treatment in adults as provided in Red book. Montvale, N.J.: Medical Economics Data, 2000. Cost to the patient will be higher, depending on prescription filling fee</span>.</p></div><div class="fn"><p class="fn"><span class="italic">Information from Relenza (zanamivir for inhalation). Package insert. Research Triangle Park, N.C.: Glaxo Wellcome, Inc., April 2000, and Tamiflu (oseltamivir phosphate) capsules. Package insert. Nutley, N.J.: Roche Laboratories Inc., 1999</span>.</p></div></div></div><div class="table-format" id="afp20001201p2467-t8"><div class="calltoactionbox"><div class="jDialog highlights"><div class="container secondary"><div class="jDialogPrintHide"><h4>TABLE 8
                                                   
                                              Comparison of Zanamivir (Relenza) and Oseltamivir (Tamiflu)</h4><p><a class="jOpener" name="afp20001201p2467-t8">
                                              View Table
                                          <                                         Comparison of Zanamivir (Relen/a></p></div><div class="jModal" title="TABLE 8" name="afp20001201p2467-t8"><div class="tableModal">
<span class="table-label">TABLE 8</span>

<h4 class="table-title">Comparison of Zanamivir (Relenza) and Oseltamivir (Tamiflu)</h4>
<table class="no-mobile-table">
<thead>
<tr>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Characteristic</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Zanamivir*</span></span></th>
<th valign="bottom" class="th" colspan="1" rowspan="1" align="left"><span class="italic"><span class="italic">Oseltamivir*</span></span></th></tr></thead>

<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Age limit for use</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">7 years and older</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">18 years and older</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Route of administration</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Oral (inhalation)</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Oral (capsule)</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Dosage</p></td>
<td t"><p class="Tabledata">Oral (inhalation)</p></td>
<td valign="top" colspan="valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">10 mg twice daily&#8224;</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">75 mg twice daily</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Precautions and warnings</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Not generally recommended in patients with asthma, COPD or other underlying airway disease; may cause bronchospasm and allergic-like reactions</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">A dosage reduction is recommended for patients with a creatinine clearance of less than 30 mL per minute (0.50 mL per second).</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Metabolism and elimination</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Renally excreted as unchanged drug Not a substrate or inhibitor of cytochrome P450 isoenzymes</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Converted to oseltamivir carboxylate primarily by hepatic esterases Not a substrate or inhibitor of cytochrome P450 isoenzymes</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Side effects</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Nasa Not a substrate or inhibitor of cytochrome P450 isoenzymes</p></td></l and throat irritation, cough, headache; bronchospasm and decreased expiratory flow rate in patients with asthma or COPD</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Nausea and vomiting, which may be reduced by administration with food</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Drug interactions</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Unlikely, but has not been studied completely</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Unlikely, but has not been studied completely</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Pregnancy category</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">C</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">C</p></td></tr>
<tr>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">Cost for five-day treatment course&#8225;</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">$44.40</p></td>
<td valign="top" colspan="1" rowspan="1" align="left"><p class="Tabledata">$53</p></td></tr></table>
<hr class="table-foot"/><div class="table-foot"><div class="fn"><p class="fn"><span class="italic">COPD = chronic obstructive pulmonary disease</span>.</p></div><div class="fnpan="1" rowspan="1" align="left"><p class="Tabledata">$53</p></td></tr></table>
<hr c"><p class="fn"><span class="italic">*&#8212;Neither zanamivir nor oseltamivir is approved for prophylaxis</span>.</p></div><div class="fn"><p class="fn">&#8224; <span class="italic">&#8212;Zanamivir is administered using a plastic device that is included in the medication package. Patients should be instructed on proper use of the device. Two inhalations (one 5-mg blister per inhalation for a total dose of 10 mg) are administered twice daily (approximately 12 hours apart) for five days. Two doses should be taken on the first day of treatment whenever possible, provided that there is at least two hours between doses. On subsequent days, doses should be taken about 12 hours apart (e.g., morning and evening) at approximately the same time each day</span>.</p></div><div class="fn"><p class="fn">&#8225;<span class="italic">&#8212;Estimated cost to the pharmacist based on average wholesale prices for treatment in adults as provided in Red book. Montvale, N.J.: Medical Economics Data, 2000. Cost to the patient will be higher, depending on prescription filling fee</span>.</p></div><div class="fn"><p class="fn"><span class="italic">Information from Relenza (zanamivir for inhalation). Package insert. Research Triangle Park, N.C.: Glaxo Wellcome, Inc., April 2000, and Tamiflu (oseltamivir phosphate) capsules. Package insert. Nutley, N.J.: Roche Laboratories Inc., 1999</span>.</p></div></div></div></div></div></div></div></div>
<h3>ZANAMIVIR</h3>
sert. Research Triangle Park, N.C.: Glaxo Wellcome, Inc., April 2000, <p>Zanamivir is administered to the respiratory tract by oral inhalation. Patient education is required on proper use of the inhaler that delivers the drug, and instructions are included in the manufacturer's package insert. Zanamivir can cause bronchospasm and decreased pulmonary function in patients with asthma or chronic obstructive pulmonary disease (COPD) and is not generally recommended for use in these patients.</p>


<p>A randomized, double-blind, placebo-controlled trial<a class="superscript" href="#afp20001201p2467-b13">13</a> conducted in 455 patients with influenza-like symptoms for less than 36 hours found that inhaled zanamivir shortened the duration of symptoms by one and one-half days in the intention-to-treat group (<span class="italic">P</span> = 0.011) as well as in influenza-positive populations (<span class="italic">P</span> = 0.004). Compared with placebo, zanamivir also reduced symptoms two days sooner in patients who were febrile (temperature greater than 37.8°C [100°F]) on enrollment (<span class="italic">P</span> &lt; 0.001). In high-risk patients, zanamivir reduced symptoms a median of two and one-half days earlier than placebo (<span class="italic">P</span> = 0.048), with significantly fewer complications (<span class="italic">P</span> = 0.004) and less complication-associated antibiotic use (<span class="italic">P</span> = 0.025). This study also found that zanamivir-treated patients returned to normal act = 0.048), with significantly fewer complications (<span class="italic">ivity two days earlier (<span class="italic">P</span> &lt;0.001) and had less sleep disturbance (<span class="italic">P</span> = 0.047) than those who received placebo.</p>

<p>Fewer adverse events were reported in zanamivir-treated patients (37 percent) than in those who received placebo (43 percent).<a class="superscript" href="#afp20001201p2467-b13">13</a> These events included bronchitis (3 percent in the treatment group versus 7 percent in the placebo group), cough (4 percent versus 6 percent), diarrhea (1 percent versus 4 percent) and nausea or vomiting (2 percent versus 4 percent). Sinusitis was more common in the treatment group (4 percent) than in the placebo group (1 percent). The authors of the study concluded that zanamivir was well tolerated and effective in reducing the duration and severity of influenza-associated symptoms.</p>

<p>Another randomized, double-blind, placebo-controlled trial<a class="superscript" href="#afp20001201p2467-b14">14</a> assessed the efficacy of zanamivir, in a dosage of 10 mg once daily, for the prevention of influenza in healthy adults. This study found that zanamivir provided 67 percent protection against laboratory-confirmed clinical influenza compared with placebo (<span class="italic">P</span>&lt;0.001) and had an efficacy of 84 percent for the prevention of laboratory-confirmed illness with fever (<span class="italic">P</span> = 0.001). During the four-week trial, the incidence of influenza compared with placebo (<span class="italic">P</span>&lt;0.001) and ha infections was reduced by 31 percent in patients who received zanamivir compared with placebo (<span class="italic">P</span> = 0.03). Adverse events were comparable to those with placebo.</p>



<p>In yet another trial,<a class="superscript" href="#afp20001201p2467-b15">15</a> patients with influenza symptoms received one of the following: intranasal zanamivir spray (6.4 mg) plus zanamivir inhalation (10 mg); zanamivir inhalation (10 mg) plus placebo spray; or placebo spray and placebo inhalation. The median duration of symptoms was reduced by one day in the patients who received zanamivir. When this antiviral agent was given within 30 hours to febrile, infected patients, symptoms were alleviated three days sooner than in those who received placebo (<span class="italic">P</span> &#8804;0.01).</p>

<p>In phase I clinical trials,<a class="superscript" href="#afp20001201p2467-b8">8</a> bronchospasm occurred after zanamivir inhalation in one of 13 patients who had mild to moderate asthma. A subset of patients with asthma or COPD experienced a 20 percent decline of forced expiratory volume in one second (FEV<sub>1</sub>) or peak expiratory flow rate compared with those who were given placebo.</p>
<p>Since zanamivir was introduced, a warning has been added recommending against use of this agent in patients with underlying airway disease (asthma, COPD) because of the risk of serious adverse events (bronchospasm and decline in lung function) bo.</p>
<p>Since zanamivir was introduced, a warning has been added reand lack of data to support efficacy in this patient population. If a patient without underlying airway disease should experience bronchospasm or a decline in respiratory function while using zanamivir, the drug should be discontinued immediately and, if necessary, hospitalization should be considered. If a physician chooses to use zanamivir in a patient with known airway disease, the patient should be made aware of the risks and should have a fast-acting bronchodilator available for use.<a class="superscript" href="#afp20001201p2467-b8">8</a></p>

<h3>OSELTAMIVIR</h3>
<p>In contrast to zanamivir, oseltamivir is administered orally. Oseltamivir is a prodrug requiring conversion by hepatic esterases to its active form, oseltamivir carboxylate. Oseltamivir carboxylate does not undergo further metabolism and is eliminated entirely by renal excretion.</p>
<p>Although oseltamivir is only indicated for the treatment of influenza, data on prevention and treatment have been studied in experimental human influenza. In the prophylaxis arm of one study,<a class="superscript" href="#afp20001201p2467-b16">16</a> influenza developed in 67 percent of patients who received placebo and in 38 percent of those who took oseltamivir (<span class="italic">P</span> = 0.16; efficacy: 61 percent). Viral shedding occurred in 50 percent of patients who were given placebo but in none who received oseltamivir (<span class="italic">P</span>&lt;0.001; efficacy: 100 pthose who took oseltamivir (<span class="italic">P</span> = 0.16; effiercent).</p>
<p>Infection-related respiratory illness developed in none of the oseltamivir-treated patients but occurred in 33 percent of those who received placebo (<span class="italic">P</span>&lt;0.01). In the treatment arm of the study, the median duration of viral shedding was reduced in the patients who received oseltamivir. Viral shedding lasted 107 hours in the placebo group but only 58 hours in the treatment group (<span class="italic">P</span> = 0.003).</p>
<p>Symptom scores were also significantly lower in patients who were given oseltamivir compared with placebo (<span class="italic">P</span> = 0.05).<a class="superscript" href="#afp20001201p2467-b16">16</a> Treated patients also had more rapid resolution of symptoms (53 hours for oseltamivir treatment versus 95 hours for placebo: <span class="italic">P</span> = 0.03). The treatment group also had a lower frequency of upper respiratory tract illness (18 percent for oseltamivir versus 54 percent for placebo), middle ear pressure abnormalities (28 percent versus 54 percent) and fever (14 percent versus 31 percent). Acetaminophen usage was also less in oseltamivir-treated patients (32 percent) than in those who were given placebo (69 percent).</p>

<p>Similar rates of adverse events were observed in the study.<a class="superscript" href="#afp20001201p2467-b16">16</a> The exception was gastrointestinal complaints, which occurred more often with oseltamivir (18 perere given placebo (69 percent).</p>

<p>Similar rates of adverse events were observedcent) than with placebo (7 percent). Mild to moderate nausea after dosing was the primary side effect, occurring in 17 percent of oseltamivir-treated patients compared with 7 percent of placebo recipients; emesis was reported in 5 percent of oseltamivir-treated patients.</p>
<p>Another prevention trial<a class="superscript" href="#afp20001201p2467-b17">17</a> concluded that oseltamivir, in a dosage of 75 mg once or twice daily for six weeks, was safe and effective. For culture-proven influenza, the protective effect of oseltamivir was 87 percent. The laboratory-confirmed infection rate was lower in the treatment group than in the placebo group (5.3 percent versus 10.6 percent, respectively: <span class="italic">P</span> &lt; 0.001).</p>
<p>In this trial,<a class="superscript" href="#afp20001201p2467-b17">17</a> nausea occurred more often in the oseltamivir-treated group (12.1 percent for once-daily treatment and 14.6 percent for twice-daily treatment) than in the placebo group (7.1 percent); vomiting was also more common in those who were given oseltamivir (2.5 percent for once-daily treatment and 2.7 percent for twice-daily treatment) compared with placebo (0.8 percent). However, the overall incidence of adverse events was similar in the three study groups (74 to 80 percent). Headache was the most common adverse event, with an incidence of 39 to 47 percent. Nearly 2 percent of patients in the placebo group withdrew from the study becauverall incidence of adverse events was similar in the three study grouse of adverse events or intercurrent illness, compared with 1.5 percent of patients in the once-daily treatment group and 1.3 percent of those in the twice-daily treatment group. Discontinuation rates were similar for oseltamivir (3.1 percent) and placebo (4.0 percent).</p>
<p>A recently published trial<a class="superscript" href="#afp20001201p2467-b18">18</a> evaluated the efficacy and safety of treatment with oseltamivir in a dosage of 75 mg taken once or twice daily. The duration of illness was reduced by 30 percent in patients treated with either dosage of oseltamivir compared with those who were given placebo (76.3 hours for once-daily treatment and 74.3 hours for twice-daily treatment versus 97 hours for placebo: <span class="italic">P</span> = 0.004). Based on symptom scores, illness severity in patients with acute influenza was reduced by 30 percent with once-daily treatment and by 38 percent with twice-daily treatment compared with placebo (<span class="italic">P</span> &lt; 0.001).</p>
<p>The recent trial<a class="superscript" href="#afp20001201p2467-b18">18</a> also found that once-daily treatment reduced the duration of cough by 43 percent and that twice-daily treatment reduced its duration by 27 percent. The duration of myalgias was reduced by 42 percent (16 hours in the treatment groups versus 28 hours in the placebo group). The duration of fever was reduced by 13 to 21 percent in the treatment group, and return to normal ced its duration by 27 percent. The duration of myalgias was reduced bactivity occurred two to three days earlier in treated patients than in the placebo group (<span class="italic">P</span> &#8804; 0.05). Bronchitis, pneumonia, otitis media and sinusitis occurred in 15 percent of the patients who were given placebo, compared with 7 percent of those treated with oseltamivir (<span class="italic">P</span> = 0.03). Although oseltamivir was well tolerated, nausea and vomiting were reported more frequently in the two treatment groups (18.0 percent for 150 mg per day of oseltamivir and 14.1 percent for 75 mg per day: <span class="italic">P</span> = 0.002) than in the placebo group (7.4 percent for 75 mg per day of placebo and 3.4 percent for 150 mg per day of placebo: <span class="italic">P</span> &lt; 0.001).</p>
<p>In a randomized trial that evaluated the resolution of illness in influenza-infected patients,<a class="superscript" href="#afp20001201p2467-b19">19</a> duration of illness was reduced by 29 hours in patients who were given oseltamivir in a dosage of 75 mg per day (mean duration of illness: 87.4 hours) and by 35 hours in those who were given 150 mg per day (mean duration of illness: 81.8 hours). Compared with the mean duration of illness in the placebo groups (116.5 hours), the reductions in the treatment groups were statistically significant (75 mg per day of oseltamivir versus placebo: <span class="italic">P</span> = 0.02; 150 mg per day of oseltamivir versus placebo: <span class="italic">P</spaacebo groups (116.5 hours), the reductions in the treatment groups wern> = 0.01). This study found that the earlier oseltamivir therapy was initiated, the sooner symptoms were reduced.</p></div>
<div class="jSection" id="sec-4">
<h2>Final Comment</h2><div class="mjToggle noPrint"><div class="mjHeader noPrint"><span style="margin:5px;">Jump to section +</span></div><div class="mjContent noPrint"><ul><li><a href="#abstract" alt="Abstract">
                                    Abstract
                                </a></li><li><a href="#sec-1">Diagnosis of Influenza</a></li><li><a href="#sec-2">Amantadine and Symmetrel</a></li><li><a href="#sec-3">Neuraminidase Inhibitors</a></li><li><a href="#sec-4">Final Comment</a></li><li><a href="#ref-list-1">References</a></li></ul></div></div>
<p>Zanamivir and oseltamivir appear to be safe and effective in the treatment of patients with acute influenza symptoms that have been present for less than 48 hours. Zanamivir generally should not be used in patients with an underlying airway disease such as asthma or COPD.</p>
<p>Clinical trials indicate that the neuraminidase inhibitors are effective in reducing the duration of influenza symptoms by one to one and one-half days if they are taken within 30 to 36 hours of symptom onset. Treatment with these agents reduces symptom severity, time to return to normal activity and the incidence of complications and antibiotic use. High-risk patients and those with a temperature greater than 37.8°C (100°F) seem to receive the moymptom onset. Treatment with these agents reduces symptom severity, timest benefit from these antiviral agents.<a class="superscript" href="#afp20001201p2467-b13">13</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b15">15</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b18">18</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b20">20</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b21">21</a> Further research should provide insight into the cost-effectiveness of treatment.</p>
<p>Although currently indicated only for the treatment of influenza, oseltamivir and zanamivir appear to be effective for prophylaxis. These antiviral agents do not reduce antibody response to the influenza vaccine, and they seem to result in less resistance compared with older agents.<a class="superscript" href="#afp20001201p2467-b11">11</a><span class="superscript">,</span><a class="superscript" href="#afp20001201p2467-b22">22</a> However, annual vaccination remains the best way to prevent influenza.</p>
<p>Data on the use of the newer antiviral agents in geriatric, high-risk and pediatric patients need to be reviewed, and the development of resistance needs to be evaluated. Trials to assess mortality, hospitalization rates and length of hospital stays should be considered.</p>
<p>Although the neuraminidase inhibitors reduce symptom severity and duration of illness, which may have potennt of resistance needs to be evaluated. Trials to assess mortality, hospitalitial public health benefit, cost and time to administration are important factors in determining the usefulness of these agents in the community setting. During isolated influenza A outbreaks, the older, less expensive antiviral agents provide both prophylaxis and treatment. Optimal use of both older and newer antiviral agents requires the prompt presentation of patients with influenza symptoms as well as fast, accurate diagnosis and prescribing by family physicians.</p></div></div></div><script xmlns:xlink="http://www.w3.org/1999/xlink">

          if (metaRestrict != 'false')
          {
          if (accTyp == 'DENIED')
          {
          $("div.jpt").addClass("journalPreviewTitle");
          $(".jptHide").css("display","block");
          $(".jptDeny").css("display","block");

          }

          else if (accTyp == 'SHOWLOGIN')
          {

          $(".jpt").addClass("journalPreviewTitle");
          $(".jptHide").css("display","block");
          $(".jptLog").css("display","block");

          };
          };
      </script><script xmlns:xlink="http://www.w3.org/1999/xlink">
          $( document ).ready(function() {

          if (metaRestrict != 'false')
          {
          if (accTyp == 'DENIED')
          {
          $(".journalPreviewLogin").css("display","block");
          $(".jptDeny").css("display","block");
          $(".pullquote").css("display","none");
          
          $("#floatNav").css("display  {
          if (accTyp == 'DENIED')
          {
          $(".journalPreview","none");
          }

          else if (accTyp == 'SHOWLOGIN')
          {
          $(".journalPreviewLogin").css("display","block");
          $(".jptLog").css("display","block");
          $(".pullquote").css("display","none");
         
          $("#floatNav").css("display","none");
          };
          };
          });
      </script><div class="journalPreviewLogin" style="display:none;" xmlns:xlink="http://www.w3.org/1999/xlink"><div class="twocolumn"><div class="content"><div class="journalPreviewContent" style=""><h4 style="padding-top:10px;text-align:center;">
                          To continue reading this article, please login or purchase online access.
                      </h4></div><hr style="color:#444444;background-color:#444444;"/><div class="journalPreviewContent" style=""><div class="left-column mobile parsys left"><div class="bobshouse section"><div class="block"><div class="container jptLog"><div style="display:block;" class="content"><div class="parsys bobpar"><div class="text parbase section"><h2>Log In for Full Access</h2><p>Online access is free for AAFP members and paid subscribers.</p></div><div class="buttonlink section"><a href="" class="button orange loginLink">
                                                      Log in<span/></a></div><p class="smalltext"><a href="http://nf.aafp.org/Account/Home/Forgot">Forgot  username</a> or <a href="http://nf.aafp.org/account/home/forgotpassword">password</ange loginLink">
                                                      >?
                                              </p></div></div></div><div class="container jptDeny"><div style="display:block;" class="content"><div class="parsys bobpar"><div class="text parbase section"><h2>Access Denied</h2><p>Online access to most content in new issues of <i>American Family Physician</i> is restricted to AAFP members and paid subscribers. All content of each issue is made freely available about one year after publication. For access to all <i>AFP</i> content, you may subscribe to the journal, purchase online access, or investigate joining the AAFP. </p></div></div></div></div></div></div></div><div class="parsys right right-column mobile"><div class="bobshouse section"><div class="block"><div class="container"><div style="display:block;" class="content"><div class="parsys bobpar"><div class="text parbase section"><h2>Purchase Online Access</h2><p>Become a subscriber, or buy online access to this issue for $29.95.</p></div><div class="buynowbutton"><div class="secondary black" style="float:left;margin-right:10px;"><input class="aafpProduct" type="button" value="Subscribe" onclick="window.location='http://www.aafp.org/journals/afp/subscriptions/rates.html';"/></div></div><div class="buynowbutton"><div style="float:left;margin:0px;line-height:16px !important;" id="BuyNowButton1" class="secondary black"><a href="" class="buyLink">Buy This Issue &gt;&gt;</a><input type="button" class="aafpProduct" value=""/></div></div</div><div class="buynowbutton"><div style="float:left;margin:0px;line><div class="text parbase section" style="clear:both;"><p class="smalltext">You will be asked to log in or create an account in order to purchase online access or subscribe.</p></div></div></div></div></div></div></div></div></div></div></div><div xmlns:xlink="http://www.w3.org/1999/xlink" class="padding-left padding-right"><h4>The Authors</h4><div class="fn"><p class="fn">NORMAN J. MONTALTO, D.O., is associate professor in the Department of Family Medicine at the Robert C. Byrd Health Sciences Center of West Virginia University/Charleston Division, Charleston Area Medical Center, Charleston, W.Va. After graduating from the College of Osteopathic Medicine and Health Sciences, Des Moines, Iowa, Dr. Montalto completed a rotating internship at Doctors' Hospital and a family medicine residency at Ohio State University, both in Columbus.</p></div><div class="fn"><p class="fn">KIMBERLY D. GUM, PHARM.D., is a pharmacy resident at Charleston Area Medical Center. She earned her doctorate of pharmacy degree at West Virginia University/Charleston Division.</p></div><div class="fn"><p class="fn">JEFFREY V. ASHLEY, M.D., is associate professor in the Department of Family Medicine at the Robert C. Byrd Health Sciences Center of West Virginia University/Charleston Division, Charleston Area Medical Center. Dr. Ashley graduated from West Virginia University School of Medicine, Morgantown, and completed a family practice residency at Charleston Area Medird Health Sciences Center of West Virginia University/Charleston Diviscal Center. He is also a registered pharmacist.</p></div><p><span class="italic">Address correspondence to Norman J. Montalto, D.O., Department of Family Medicine, Robert C. Byrd Health Sciences Center of West Virginia University/Charleston Division, 1201 Washington St. East, Ste. 108, Charleston, W V 25301. Reprints are not available from the authors</span>.</p>
<div class="ref-list" id="ref-list-1">
<h3>REFERENCES</h3><div class="mjToggle noPrint"><div class="mjHeader noPrint"><span style="margin:5px;">Jump to section +</span></div><div class="mjContent noPrint"><ul><li><a href="#abstract" alt="Abstract">
                                    Abstract
                                </a></li><li><a href="#sec-1">Diagnosis of Influenza</a></li><li><a href="#sec-2">Amantadine and Symmetrel</a></li><li><a href="#sec-3">Neuraminidase Inhibitors</a></li><li><a href="#sec-4">Final Comment</a></li><li><a href="#ref-list-1">References</a></li></ul></div></div>
<p id="afp20001201p2467-b1"><span class="label">1. </span><span class="citation"> Mortality patterns&#8212;United States, 1997. <i>MMWR Morb Mortal Wkly Rep</i>.
       1999;48:664&#8211;8.</span></p>
<p id="afp20001201p2467-b2"><span class="label">2. </span><span class="citation">Schoenbaum SC. Impact of influenza in persons and populations. In: Brown LE, Hampson AW, Webster RG, eds. Options for the control of influenza III: proceedings of the third International Conference on Option class="label">2. </span><span class="citation">Schoenbaum SC. Impact of is for the Control of Influenza, Cairns, Australia, 4&#8211;9 May, 1966. New York: Elsevier, 1996:17&#8211;25.</span></p>
<p id="afp20001201p2467-b3"><span class="label">3. </span><span class="citation"> Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>.
       1999;48(RR-4):1&#8211;28.</span></p>
<p id="afp20001201p2467-b4"><span class="label">4. </span><span class="citation"> Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Morb Mortal Wkly Rep</i>.
       2000;49(RR-3):1&#8211;38.</span></p>
<p id="afp20001201p2467-b5"><span class="label">5. </span><span class="citation">Dolin R. Infectious disease. In: Fauci AS, et al., eds. Harrison's Principles of internal medicine. 14th ed. New York: McGraw-Hill, Health Professions Division, 1998:1112&#8211;6.</span></p>
<p id="afp20001201p2467-b6"><span class="label">6. </span><span class="citation">Is it a cold or the flu? Retrieved October 9, 2000, from: <a rel="nofollow" href="http://www.niaid.nih.gov/publications/cold/sick.htm">http://www.niaid.nih.gov/publications/cold/sick.htm</a>.</span></p>
<p id="afp20001201p2467-b7"><span class="label">7. </span><span class="citation">Bukrinskaya AG,
        Vorkunova NK,
        Kornilayeva GV,
        Narmanbetova RA,
        Vorkunova GK.
         Influenza virus uncoating iold/sick.htm</a>.</span></p>
<p id="afp20001201p2467-b7"><span class="label">7. <n infected cells and effect of rimantadine. <i>J Gen Virol</i>.
       1982;60(pt 1):49&#8211;59.</span></p>
<p id="afp20001201p2467-b8"><span class="label">8. </span><span class="citation">Relenza (zanamivir for inhalation). Package insert. Research Triangle Park, N.C.: Glaxo Wellcome, Inc., April 2000.</span></p>
<p id="afp20001201p2467-b9"><span class="label">9. </span><span class="citation">Tamiflu (oseltamivir phosphate) capsules. Package insert. Nutley, N.J.: Roche Laboratories Inc., 1999.</span></p>
<p id="afp20001201p2467-b10"><span class="label">10. </span><span class="citation">Calfee DP,
        Hayden FG.
         New approaches to influenza chemotherapy. Neuraminidase inhibitors. <i>Drugs</i>.
       1998;56:537&#8211;53.</span></p>
<p id="afp20001201p2467-b11"><span class="label">11. </span><span class="citation">von Itzstein M,
        Wu WY,
        Kok GB,
        Pegg MS,
        Dyason JC,
        Jin B,
        
          et al.
         Rational design of potent sialidase-based inhibitors of influenza virus replication. <i>Nature</i>.
       1993;363:418&#8211;23.</span></p>
<p id="afp20001201p2467-b12"><span class="label">12. </span><span class="citation"> Neuraminidase inhibitors for treatment of influenza A and B infections. <i>MMWR Morb Mortal Wkly Rep</i>.
       1999;48(RR-14):1&#8211;9.</span></p>
<p id="afp20001201p2467-b13"><span class="label">13. </span><span class="citation"> Randomised trial of efficacy idase inhibitors for treatment of influenza A and B infections. <i>MMWand safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. <i>Lancet</i>.
       1998;352:1877&#8211;81 [Published errata appear in Lancet 1999;353:504 and 1999;353: 1104]</span></p>
<p id="afp20001201p2467-b14"><span class="label">14. </span><span class="citation">Monto AS,
        Robinson DP,
        Herlocher ML,
        Hinson JM,
        Elliott MJ,
        Crisp A.
         Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. <i>JAMA</i>.
       1999;282:31&#8211;5.</span></p>
<p id="afp20001201p2467-b15"><span class="label">15. </span><span class="citation">Hayden FG,
        Osterhaus AD,
        Treanor JJ,
        Fleming DM,
        Aoki FY,
        Nicholson KG,
        
          et al.
         Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus Infections. GG167 Influenza Study Group. <i>N Engl J Med</i>.
       1997;337:874&#8211;80.</span></p>
<p id="afp20001201p2467-b16"><span class="label">16. </span><span class="citation">Hayden FG,
        Treanor JJ,
        Fritz RS,
        Lobo M,
        Betts RF,
        Miller M,
        
          et al.
         Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. <i>JAMA</i>.
       1999;28     Lobo M,
        Betts RF,
        Miller M,
        
          et2:1240&#8211;6.</span></p>
<p id="afp20001201p2467-b17"><span class="label">17. </span><span class="citation">Hayden FG,
        Atmar RL,
        Schilling M,
        Johnson C,
        Poretz D,
        Paar D,
        
          et al.
         Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. <i>N Engl J Med</i>.
       1999;341:1336&#8211;43.</span></p>
<p id="afp20001201p2467-b18"><span class="label">18. </span><span class="citation">Treanor JJ,
        Hayden FG,
        Vrooman PS,
        Barbarash R,
        Bettis R,
        Riff D,
        
          et al.
         Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. <i>JAMA</i>.
       2000;283:1016&#8211;24.</span></p>
<p id="afp20001201p2467-b19"><span class="label">19. </span><span class="citation">Nicholson KG,
        Aoki FY,
        Osterhaus AD,
        Trottier S,
        Carewicz O,
        Mercier CH,
        
          et al.
         Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. <i>Lancet</i>.
       2000;355:1845&#8211;50.</span></p>
<p id="afp20001201p2467-b20"><span class="label">20. </span><span class="citation">Monto AS,
        Fleming DM,
        Henry D,
        de Groot R,
        Makela M,
        KlInvestigator Group. <i>Lancet</i>.
       2000;355:1845&#8211;50.</spaein T,
        
          et al.
         Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. <i>J Infect Dis</i>.
       1999;180:254&#8211;61.</span></p>
<p id="afp20001201p2467-b21"><span class="label">21. </span><span class="citation"> Two neuraminidase inhibitors for treatment of influenza. <i>Med Lett Drugs Ther</i>.
       1999;41(1063):91&#8211;3.</span></p>
<p id="afp20001201p2467-b22"><span class="label">22. </span><span class="citation">Gubareva LV,
        Matrosovich MN,
        Brenner MK,
        Bethell RC,
        Webster RG.
         Evidence for zanaminivir resistance in an immunocompromised child infected with influenza B virus. <i>J Infect Dis</i>.
       1998;178:1257&#8211;62.</span></p></div><p class="blurb"><span class="italic">Richard W. Sloan, M.D., R.PH., coordinator of this series, is chairman and residency program director of the Department of Family Medicine at York (Pa.) Hospital and clinical associate professor in family and community medicine at the Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pa</span>.</p><div class="commenting" id="commenting"><div class="showCommentsLink"><button class="button orange addViewComments">Add/view comments</button></div><div class="hideCommentsLink"><button class="button orange hideComments">Hide comments</button></div><div class="commCount"><span style="display:none;"><br/></spowCommentsLink"><button class="button orange addViewComments">Add/viewan></div><div class="comments">
     


<script language="JavaScript" type="text/javascript" src="http://www.aafp.org/javascript/cookieutil.js"></script>
<script>

// has Community server cookie
var communityCookie = getCookie("CSUser");
var uCookie = getCookie("U");
var commenthandleURL = "http://community.aafp.org/f/28/embed.aspx";

if(uCookie != null &&  uCookie.length > 0){
 $(".showCommentsLink").css('display', 'block');
  document.write('<div class="articleComments"><scr'+'ipt type="text/javascript" src="http://www.aafp.org/cgi-bin/cscommentjs.pl?commenthandleURL=' + commenthandleURL + ''+'"></sc'+'ript></div>');
}
else{ 
   //alert(encodeURIComponent(window.location));
   document.write("<div class='EmbeddedForumHeaderAreaImage'><img src='http://www.aafp.org/images/telligent/comment-icon.jpg'></img></div><div class='EmbeddedForumHeaderArea'><h3>Comments</h3><p>You must be logged in to view the comments.  <a href=\"http://www.aafp.org/cgi-bin/lg.pl?redirect="+encodeURIComponent(window.location)+"#commenting \" >Login</a></p></div>");
}



 
 function limitCharsJournalCommenting()
 {
   limit = 1200
   infodiv = 'charlimitinfoJournalCommenting';
  
   text = $('#commenting textarea').val();
   textlength = text.length;
   if(textlength > limit){
   $('#' + infodiv).html('You cannot write more then '+limit+' characters!');
   $('#commenting textarea').val(text.substr(0,limit));
   return false;
   }
   else{
   $('#' + infodiextarea').val();
   textlength = text.length;
   if(textlength > limit){
   $v).html('You have '+ (limit - textlength) +' characters left.');
   return true;
   }
 }
 
$(document).ready(function(){
  setTimeout('bindLimit()', 1000);
 });

 function bindLimit(){
 
  $('#commenting textarea').live('keyup', function(){
   //alert("test");
  
   //check to see if div is present if not add it
   if($('#charlimitinfoJournalCommenting').length == 0){
    $('#commenting textarea').after('<div class="smtext red" id="charlimitinfoJournalCommenting"></div>');
   }
  
   limitCharsJournalCommenting();
  })
 }
 
 



</script>


      <script type="text/javascript">
          $(document).ready( function() {
         


          $("#commenting").append("<p><i>All comments are moderated and will be removed if they violate our <a href=\"http://www.aafp.org/journals/afp/permissions/terms-use.html\">Terms of Use</a>.</i></p>");
          });
      </script>








</div></div><br/><p class="journalCopyright">
            Copyright © 2000 by the American Academy of Family Physicians.<br/>
            This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact  
             <a href="mailto:afpserv@aafeference. This material may not otherwise be downloaded, copied, printed, storep.org">afpserv@aafp.org</a> for copyright questions and/or permission requests.
          </p></div><script xmlns:xlink="http://www.w3.org/1999/xlink">
          $(document).ready(function() {
          var $commentsImg = $(".EmbeddedForumHeaderAreaImage")
          var $commentsCount = $(".EmbeddedForumHeaderArea")[0]
          $( ".commCount").prepend($commentsImg, $commentsCount);
          });


          $( ".addViewComments" ).click(function() {
          var $commentsImg = $(".EmbeddedForumHeaderAreaImage")
          var $commentsCount = $(".EmbeddedForumHeaderArea")[0]
          $(".leaderboardAd, .rightBoxAd, .mobile-ad, .showCommentsLink").attr("style", "display: none !important");
          $(".articleComments, .hideCommentsLink, .EmbeddedForumPosts").attr("style", "display: block !important");
          $( ".articleComments div:first").prepend($commentsImg, $commentsCount);
          });

          $( ".hideComments" ).click(function() {
          var $commentsImg = $(".EmbeddedForumHeaderAreaImage")
          var $commentsCount = $(".EmbeddedForumHeaderArea")[0]
          $(".leaderboardAd, .rightBoxAd, .mobile-ad, .showCommentsLink").attr("style", "display: block !important");
          $(".articleComments, .hideCommentsLink, .EmbeddedForumPosts").attr("style", "display: none !important");
          $( ".commCount").prepend($commentsImg, $commentsCount);
          });
      </script><script xmlns:xlink="http://www.w3.org/1t");
          $(".articleComments, .hideCommentsLink, .EmbeddedForumP999/xlink">
     

          $(document).ready(function() {
          var contentType = $("meta[name='content-type-facet']").attr("content");
         


          if  (($("#floatNavLinks").length) && (contentType == 'Article') && (accTyp !== 'DENIED') && (accTyp !== 'SHOWLOGIN')){
        


          $("#floatNav").addClass("showScreen");
          };
          
          if (contentType !== 'Article') {
        

          $("#floatNav").css("display", "none");
          };
          });


</script><script type="text/javascript" xmlns:xlink="http://www.w3.org/1999/xlink">
$(document).ready(function(){
    $(".mjContent").hide();
    $(".mjHeader").toggle(function(){
        $(this).html('<span style="margin:5px;">Jump to section -</span>');
        }, function () {
        $(this).html('<span style="margin:5px;">Jump to section +</span>');
    });
    $(".mjHeader").click(function(){
        
        $(this).nextAll(".mjContent").slideToggle();
    });
});
</script><script type="text/javascript" xmlns:xlink="http://www.w3.org/1999/xlink">
          var buyName ="afp-december-1-2000-online-access";
    
      </script><script type="text/javascript" xmlns:xlink="http://www.w3.org/1999/xlink">



          AAFP.Core.use("ProductManager", function () {


          AAFP.ProductManager.config.buttonText = "Buy This Issue";
          AAFP.ProductManager.config.showImage = false;
          AAFP.ProductManager.config.showName = false;
       xlink">



          AAFP.Core.use("ProductManager", function () {


    AAFP.ProductManager.config.showDescription = false;
          AAFP.ProductManager.config.showPrices = false;
          AAFP.ProductManager.config.showButton = true;
          AAFP.ProductManager.buildProduct("single-issue-cme", buyName, "BuyNowButton1");



          });

      </script>

		

					<div class="align-center">

						
 












      <div class="sharebox share">


<script src="//js.aafp.net/components/content/share/share.js" type="text/javascript"></script>

<style type="text/css">
	
	.at16t_compact {
			background-image: none !important;
		}
	#aafpConnectionMessage {
	line-height: 1.1em;
	width: 100%;
	margin-top: 5px;
	}
</style>



			<script type="text/javascript">
 var addthis_share = { email_template: 'aafp' }
 var addthis_config = {
   username: "aafponline"
   , ui_click: true
   , ui_cobrand: "AAFP"
   , services_compact: 'email, google_plusone_share, delicious, reddit, linkedin, instapaper, pocket, evernote, more'
   , services_exclude: 'print'
   }
 </script>

		<p>Share this page</p>
		<div class="icons">
			
			
			<script type="text/javascript" src="https://s7.addthis.com/js/250/addthis_widget.js"></script>
	
			<a title="Bookmark and Share" class="addthis_button_compact sharethis at300m" style="margin: 0 5px;float:left;" href="http://www.addthis.com/bookmark.php?v=250&amp;username=aafponline"><img alt="Bookmark and Share" height="24" width="24" s/script>
	
			<a title="Bookmark and Share" class="addthis_button_corc="http://img.aafp.net/icons/addthis.png" /></a>
			
			<a title="Share to Facebook" class="addthis_button_facebook icon facebook at300b" href="#">Facebook</a>
			<a title="Share to Twitter" class="addthis_button_twitter icon twitter at300b" href="#">Twitter</a>			
			
			<a class="icon print" title="Print page" onclick="window.print(); return false;" href="#">Print</a>
			<!-- <a href="?printable=afp" title="Print page" class="icon print">Print</a> -->
		</div>
		




		






<script type="text/javascript">
$(document).ready(function() {
	$('#aafp-sign-in').attr('href',loginInfo.signInPageLinkInfo.url);
});
</script></div>



            
         
          
<div class="clearfix"></div>





 
 

						<p>Want to use this article elsewhere? <a href="http://www.aafp.org/journals/afp/permissions/requests.html ">Get Permissions</a></p>
						
						
	
						 

					</div><!-- align-center -->

					<div class="clearfix"></div>

				</div><!-- container -->

			</div><!-- eight-column -->

	
		</div><!-- bucket -->

		 







 <div class="bucket short" id="column-wrap">










    
    
      <!-- Begin EHS Body Tag -->
      <div class="noindex align-center rightBoxAd" style="margin:0px auto 20px auto;text-align:center;z-index:1000;">
        <a class="advert-title" href="http://www.aafp.org/journals/afp/advertisers/rates-policies/online-policies.html" tHS Body Tag -->
      <div class="noindex align-center rightBoxAd" style="mararget="_blank">Advertisement</a><br>

   <script type="text/javascript">
//<![CDATA[
EHS_AD("t", "l", "300x250");
//]]>
</script>
      </div>
      <!-- End EHS Body Tag -->
    












<div class="block four-column drop-shadow no-margin tablet-no-resize" style="margin-left:0px;">
			<div class="container white">

			<p class="title">Article Tools</p>

 <div class="content">

 
 <ul>
 

     

           



           <li style="background:none;left:.4em;list-style-type:none;" class="commentLink">
			<img alt="" src="https://www.aafp.org/afp/images/icons/comment20.gif" height="17" width="17" />
			<strong><a class="sidenav" href="#commenting">Comments</a></strong>
          </li>
         
         <script>
          if ($('#commenting').length) {
        
          $('.commentLink').show();}

          else {
	
          $('.commentLink').hide();
};
           
          </script>


   


           <li style="background:none;left:.4em;list-style-type:none;" class="gtIE8">
			<img alt="" src="//img.aafp.org/icons/print.png" height="17" width="17" />
			<strong><a id="printPage" class="sidenav" style="cursor:pointer">Print page</a></strong>
          </li>
  
        
        <li style="background:none;left:.4em;list-style-type:none;display:none;" id="printTablesFiguresLink" class="gtIE8">
			<img alt="" src="//img.aafp.org/icons/print.png" height="17" width="17" />t page</a></strong>
          </li>
  
        
        <li style="backgro
			<strong><a id="printTabFig" style="cursor:pointer">Print tables and figures</a></strong>
          </li>
          
       
       
          
          <li style="background:none;left:.4em;list-style-type:none; display:none" class="ltIE8">
          <img alt="" src="//img.aafp.org/icons/print.png" height="17" width="17" />
          <strong><a onclick="window.print(); return false;" href="#">Print Page</a></strong>
          </li>
       
          
  <!--[if lt IE 9 ]>       
       <script type="text/javascript">
 
       $('.gtIE8').css('display', 'none');
       $('.ltIE8').show();
       </script>       
   <![endif]-->
   
   
 
  <!--[if !IE | gte IE 9]><!-->    
 <script>          
         
          $(document).ready(function() {       	 
        	  
        	  
        	var printWrap = $("<div>", {class: "printVersion"});
     		var titleGroup = $(".titleGroup").clone();	
        	var thisBody = $("body").clone();
            var articleContent = $(".articleContent").clone();
            var commentHead = $(".EmbeddedForumHeaderArea").clone(); 
            var commentPosts = $(".EmbeddedForumPosts").clone(); 
            var journalCopyright = $(".journalCopyright").clone(); 
           
            
            
            $(articleContent).find("h1.article-title").css('font-size', '28px');
            $(articleContent).appendTo(printWrap).end();
            $(commentHead).appendight = $(".journalCopyright").clone(); 
           
            
  To(printWrap).end();
            $(commentPosts).appendTo(printWrap).end();
            $(journalCopyright).css('display', 'block').appendTo(printWrap).end();
      
 			

          $("#printPage").click (function(){
        	 
        	  
        	  $(printWrap).find("a").removeAttr("href");
	
    	   $(printWrap).printElement(
    			   
    			
    	            {pageTitle: '',
    	               
    	                printBodyOptions:
    	                {
    	               
    	             
    	                            		
    	                            		 styleToAdd:'width:auto;margin:15px;background-color:#ffffff !important;}',
    	                 	                classNameToAdd : 'printVersion'
    	                 	                },
    	                 	               printMode:'popup',
    	                            		 leaveOpen:true,
    	                 	                }

        
    	   );
    	   
    	   });
          
      });
          </script>         
          
            <script>
     $(document).ready(function() {
    	 
    	  	 
    	 if ($(".tableModal").length > 0 || $(".figModal").length > 0){
    		

$("#printTablesFiguresLink").css('display', 'block');

     	};
    	 
     });
     </script>
     
     
  
          
          <script>
          
         
          $(document).ready(function() {
        	  
        	  var pri  		

$("#printTablesFiguresLink").css('display', 'block');

     ntWrap = $("<div>", {class: "printVersion"});
        	  var titleGroup = $(".titleGroup").clone();       
         	  var theseTables =  $(".printTable").clone();         
              var theseFigs =  $(".printFigure").clone();                            
              var journalCopyright = $(".journalCopyright").clone(); 
              
         
            
             
              $(titleGroup).find("h1.article-title").css('font-size', '28px');
             $(titleGroup).appendTo(printWrap).end();
        	 $(theseTables).appendTo(printWrap).css('display', 'block').end();
        	 $(theseFigs).appendTo(printWrap).css('display', 'block').end();
  			 $(journalCopyright).css('display', 'block').appendTo(printWrap).end();
  			 
  			
          
          $("#printTabFig").click (function(){
        	  
        	 
        	  
        	  $(printWrap).find("a").removeAttr("href");
        
        	  	
        	 $(printWrap).printElement(
        	
    			 
    	            {pageTitle: '',
    	               
    	                printBodyOptions:
    	                {
    	               
    	               
    	             
    	                            		
    	                            		 styleToAdd:'width:auto;margin:15px;background-color:#ffffff !important;}',
    	                 	                classNameToAdd : 'printVersion'
    	                 	                },
    	                   		
    	                            		 styleToAdd:'                	               printMode:'popup',
    	                            		 leaveOpen:true,
    	                 	                }

        
    	   );
    	   
    	   });
          
      });
          </script>
          
          
       <![endif]-->     
           
        
       <!-- AddThis Button BEGIN --> 



       <li style="background:none;left:.4em;list-style-type:none;">
       <img src="https://www.aafp.org/afp/images/icons/share20.gif" height="17" width="17" /> <strong>     
<a href="http://www.addthis.com/bookmark.php?v=250&amp;username=aafponline" class="sidenav addthis_button_compact">Share this page</a> </strong> </li>
		
<!-- ADDTHIS BUTTON END -->
		 

            <li style="background:none;left:.4em;list-style-type:none;">
            <img alt="" src="https://www.aafp.org/afp/images/icons/quiz20.gif" height="17" width="17" />
           <strong> <a class="sidenav" href="/afpquiz/">AFP CME Quiz</a></strong>
          </li>
           <!-- <li style="background:none;left:.4em;list-style-type:none;">
            <a class="sidenav" href="http://www.copyright.com/ccc/openurl.do?ourl_company=American%20Academy%20of%20Family%20Physicians&amp;issn=0002-838X&amp;WT.mc_id=pub_American%20Academy%20of%20Family%20Physicians">
              <img alt="Get Permissions" src="http://www.aafp.org/journals/icons/ccc.gif" height="15" width="101" />
            </a>
          </li>-->y%20Physicians&amp;issn=0002-838X&amp;WT.mc_id=pub_American%20Academy%
					</div>

    </div>
    </div>
	

	

	









<script>  $(document).ready(function() {if ($('#micro-sites p').length > 0)
	
	$('#msBox').show();
	
	});</script>


   
	<div id="msBox" >	
<div class="center block four-column drop-shadow no-margin microSite" style="text-align:center;margin-bottom:15px;">
<div style="background-color:#ffffff;width:300px;display:inline-block;" class="">

            

    		<p style="background-color:#bb3333;color:#ffffff;
    border-bottom-style: solid;
    border-bottom-width: 1px;margin:0;padding:0;text-transform:uppercase;font-weight:normal;">Information From Industry</p>
    <div style="text-align:left;margin:10px;">
   
<div style="font-size:8pt;" id="micro-sites">
     	<script type="text/javascript">
//<![CDATA[
EHS_AD("t", "l", "160x225");
//]]>
</script>
    	
</div>
 </div>
</div>
</div>
</div>

<div class="clearfix"></div>

<!-- <div style="border:1px solid #000000;width:100%;" id="msBox">

<div id="msBoxHead" style="background-color:#990000;color:#FFFFFF;font-family:Arial, Helvetica, sans-serif !important;font-weight:bold;font-size:11px;padding:3px;">ADVERTISEMENT</div>

<div id="micro-sites">

<script type="text/javascript">
//<![CDATA[
EHS_AD("t", "l", "160x225");
//]]>
</script>

</div>
</div>
 -->









		
		
		








	
	
	
	
	          
	
	
	
	
	
	
			
			<div class="block  id="micro-sites">

<script type="text/javascript">
//<![CDATA[
EHS_AD("tfour-column drop-shadow no-margin tablet-no-resize">
			<div class="container white">

			<p class="title">More in Pubmed</p>

 <div class="content">
<br />
						<ul class="bold">
							<li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11130232">Citation</a></li>
							<li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Display&amp;dopt=pubmed_pubmed&amp;from_uid=11130232">Related Articles</a>
							</li>
						</ul>

					</div>

    </div>    
    </div>

       




	
		








<div class="block four-column drop-shadow no-margin tablet-no-resize" style="margin-left:0px;">
			<div class="container white">

			<p class="title">AFP Resources</p>

 <div class="content">
 <br />
 	<ul class="bold">
				            <li><a href="http://www.aafp.org/journals/afp/about/contact.html">About AFP</a></li>
							<li><a href="http://www.aafp.org/journals/afp/permissions/terms-use.html">Permissions</a></li>							
							<li><a href="http://www.aafp.org/journals/afp/subscriptions/rates.html">Subscribe</a></li>
							<li><a href="http://www.aafp.org/journals/afp/authors/guide.html">For Authors</a></li>
							<li><a href="http://www.aafp.org/journals/afp/reviewers/guide.html">For Reviewers</a></li>
							<li><a href="http://www.aafp.org/journals/afp/advertisers/rates-policies.html">For Advertisers<ournals/afp/authors/guide.html">For Authors</a></li>
							<li><a href="http/a></li>
						
						</ul>
 </div>
  </div>
</div>










<div class="block four-column drop-shadow no-margin tablet-no-resize" style="margin-left:0px;">
	
    <div class="container white">
        <p class="title">Stay Connected</p>

        <div class="content">
            <div class="parsys bobpar">
            
            <div class="socialbiolink section">

	
		
		<ul class="bioLinkStandalone">
			<li>
				<a href="https://www.facebook.com/AFPJournal" class="text facebook"><span class="icon"></span> American Family Physician</a>
			</li>
		</ul>
	
	
</div>
<div class="socialbiolink section">

	
		<ul class="bioLinkStandalone">
			<li>
				<a href="https://twitter.com/AFPJournal" class="text twitter"><span class="icon"></span> @AFPJournal</a>
			</li>
		</ul>
	
</div>
<div class="socialbiolink section">

		
		<ul class="bioLinkStandalone">
			<li>
				<a href="http://www.youtube.com/AFPJournal" class="text youtube"><span class="icon"></span> AFP Videos</a>
			</li>
		</ul>
	
	
	
	

</div>

</div>

        </div>
    </div>
</div>

















<div class="block four-column drop-shadow no-margin tablet-no-resize" id="floatNav">
			<div class="container white">

			<p class="title">Navigate this Article</p>

 <div class="content">
  <br />
  <span id="floatNavSpace"></span>
  
  
 



 </div>
  </div>
</div>	





<script>in tablet-no-resize" id="floatNav">
			<div class="container white">



$(document).ready(function() {

	if (document.getElementById("floatNavLinks")) {
		
		   $("#floatNavLinks").appendTo("#floatNavSpace");
		   
		   $("#floatNav").show;
	};
	
});

</script>
<script>
	
	
    
$(document).ready(function() {
	
	
	
      offsetF = $("#floatNav").offset().top;     
      sideBarH = $("#floatNav").height();
    var topPadding = 20; 
    	
      
     function scrollThis() {     
    	 
 
    	 
     
    	 
    	
    	    var maxPos = $("#leaderBoardAd").height() + $("#header-container").height() + $(".wide").height() - (sideBarH);
            
            var maxPosB = $(".wide").offset().top + $(".wide").height() - (sideBarH + offsetF + 50);
                        
            var newPos = ($(document).scrollTop() - offsetF) + topPadding;
            
                        
            if ($(document).scrollTop() > offsetF) {
            	
            	
                if (newPos > maxPosB) {
                	
                	
                	 
                	 $("#floatNav").stop().animate({
                         marginTop: (maxPosB - 20)
                     });
                	 
                	 
                }
                
                else{
                	  
           
                $("#floatNav").stop().animate({
                    marginTop: newPos
                });
             
                }
              	 
                }
                
                else{         
            } 
            
            else {
            
                $("#floatNav").stop().animate({
                    marginTop: 0
                });
            };
            
       
        };
   
       
    	$(window).scroll(function() {          
    		
    		
    		scrollThis();
    		
    	});
        
        
    	$(window).resize(function() {   
    		  
    	     var wideNess = $(".wide").offset().top + $(".wide").height() - (($("#floatNav").height()) + offsetF + 50);
             var floatMarg = parseInt($("#floatNav").css('margin-top'));
         
            
            
            
             		
             		if(wideNess < floatMarg){
             	
             			
             			 $("#floatNav").css('margin-top', wideNess);
                    	 
             		}; 
    		
    		scrollThis();
    		
    		});
        
    });


  

	

	
    
	</script>	
	
	 
	
	
	<script>

	</script>
	
		<script>	
	$(document).ready(function() {
		
			
			
			$('a.floater').unbind("click").bind("click", function (event) {
								
				srcText = "side:" + jQuery.trim($(this).text());		        	
	        	
	    		var s=s_gi(s_account);	    		
	    		s.prop31 = srcText;
	    		
	    		s.prop33=(s.pageName + ":" + s.prop31); 
	    		
	    		s.linkTrackVars="prop31,prop33";
	    		s.linkTrackEvents="none";
	    	
			
			});
			
			
	  
	        	
	    		var s=s_gi(s_account);	    		
	    		s.prop31 = s      
		 });
	</script>
	
	
	


</div>


		<div class="clearfix"></div>

		

	</section><!-- content -->

	<div class="clearfix"></div>

</div><!-- main -->

     <div class="clearfix"></div>   
 
 	 








<div id="aafpSyndicatedBreadcrumbs" style="display:none;">
 <p><a href="http://www.aafp.org">Home</a> 
 <span>/</span> <a href="http://www.aafp.org/journals.html">Journals</a> 
 <span>/</span> <a href="/afp/" style="text-transform:uppercase">afp</a> 
 <span>/</span> <a href="/afp/2000/1201/">Vol. 62/No. 11(December 1, 2000)</a> 
 <span>/</span>  
    
      Updated Treatment for Influenza A and B
    
 </p>
</div> 


  
        <!-- breadcrumbs-container -->

       
     

        <!--#include virtual="includes/mobile-footer.html" -->

 <script type="text/javascript" src="https://www.aafp.org/journals/afp.footer.js"></script>
    
          
    
    
    
        <script>
     $(document).ready(function() {
(function($){
	$.getQuery = function( query ) {
		query = query.replace(/[\[]/,"\\\[").replace(/[\]]/,"\\\]");
		var expr = "[\\?&]"+query+"=([^&#]*)";
		var regex = new RegExp( expr );
		var results = regex.exec( window.location.href );
		if( results !== null ) {
			return results[1];
			return decodeURIComponent(results[1].replace(/\+/g, " "));
		} else {
			return false;
		}
	};
})(jQuery);
 
// Document load
$(function(){
	var appTraffic = $.getQuery('mobile');
 
	
	if(appTraffic == 'afpMobile')
	{
   
	
$(".primary-nav, .global-search, .mobilenav, #utility-nav").css({'visibility':'hidden'});
$(".share, .breadcrumbs, #footer-container, .mobile-navigation").css({'display':'none'});

	
} 
});
     });
  </script>
  
        <script>
     
          $(document).ready(function() {
          var contentType = $("meta[name='content-type-facet']").attr("content");
         


          if  (($("#floatNavLinks").length) && (contentType == 'Article') && (accTyp !== 'DENIED') && (accTyp !== 'SHOWLOGIN')){
        


          $("#floatNav").addClass("showScreen");
          };
          
          if (contentType !== 'Article') {
        

          $("#floatNav").css("display", "none");
          };
          });

      </script>
      
 
  </body>
</html>      $("#floatNav").addClass("showScreen");
          };
          
          if (contentType !== 'Article') {
        

          $("#floatNav").css("display", "none");
          };
          });

      </script>
     